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Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in 
developed nations, and heart disease is predicted to remain the leading killer for the 
foreseeable future. Acute myocardial infarctions (MI)—1.2 million annually occurring in 
the U.S. alone—are the major CVD subgroup. Blood supply to the heart is occluded 
during MI, and the ensuing hypoxic and anemic hypoxia triggers deleterious responses 
within the affected tissue, affecting cardiomyocyte (CM) and endothelial cell function and 
viability. Largely non-regenerative, the pressure overload leads to non-contractile scar 
formation and the infarcted heart undergoes a degenerative process toward heart failure. 
Beyond immediate treatments to restore coronary blood flow, the medical community 
lacks therapeutic strategies to effectively intervene in the long-term progression of 
cardiac dysfunction. 
The first section of this thesis examines two synthetic drug delivery vehicles to 
mitigate myocyte cell death and enhance vasculogenesis. The second part focuses on 
amplifying endogenous cardiac signals to treat the heart, and elucidating clues from said 
signals for bio-inspired therapeutics. 
Although many drugs exist that may aid ischemic myocytes, intracellular delivery 
of such drugs remains a hurdle, owing to the non-phogocytic nature of myocytes. Here, 
we describe a novel drug delivery system that relies on surface decoration with N-
acetylglucosamine (GlcNAc) to induce internalization. We tested the ligand with an acid-
degradable polymeric nanoparticle poly(cyclohexane-1,4-diyl acetone dimethylene ketal)  
(PCADK) encapsulating an anti-apoptotic small molecule, SB239063. The vehicle 
mitigated the effects of MI in a rat model: it reduced cell death in vivo and improved 
cardiac function. We also developed a dendrimeric delivery vehicle that exhibited region-
selective decoration with the internalizing tripeptide arginine-glycine-aspartic acid (RGD) 
 xix 
and loaded it with the angiogenic microRNA, miR-126. This vehicle promoted 
vasculogenesis in vitro and may prove useful in enhancing blood flow within the infarcted 
cardiac zone. 
A small population of stem cells resides in the heart, termed cardiac progenitor 
cells (CPCs). We collected the exosomes secreted in various conditions and treated 
cardiac endothelial and fibroblast cell lines with concentrated doses of the exosomes. 
The hypoxic exosomes enhanced tube formation of endothelial cells and attenuated 
cytokine stimulation of fibroblasts, indicating that they may restore blood flow to the 
infarct and mitigate excessive scar formation in the heart. We characterized the miR 
signature that CPCs release in response to hypoxic conditions and found several to be 
upregulated in secreted exosomes. Statistical analysis revealed clusters of co-varying 
miRs and predicted their physiological response, laying groundwork for development of 









The National Institutes of Health estimates that among the current population, 7.9 
million Americans have suffered acute MI.1 Current treatments are limited to immediate 
intervention, including angioplasty and thrombolysis, which serve to restore blood flow to 
the infarcted region and thereby mitigate further damage, but fail to regenerate tissue. 
During the ischemic injury and in subsequent reperfusion,2 deleterious signaling 
cascades in the affected tissue are triggered, leading to localized death at the cellular 
level.3 As adult CMs are terminally differentiated4 and relatively non-proliferative,5 the 
ischemic insult leads to eventual dysfunction and failure at the organ level6; rather than 
regenerate, the heart forms a non-contractile fibrotic scar in the infarct region that is key 
to subsequent degeneration. Because the initial cell death is primarily regional,7 
localized therapy to target and reverse the damage by protecting or regenerating CMs or 
restoring blood flow to the injured myocardium is quite promising. 
Apoptotic pathways are complex and include many molecules, including whose 
activation either promote or inhibit cell death, such as Bcl-2,8, 9 Bcl-xL,10 and XIAP.11 
Other proteins outside of apoptotic pathways also improve cell survival, such as 
superoxide dismutase (SOD) and catalase that attenuate oxidative stress produced 
during ischemia–reperfusion (IR) injury.12 Furthermore, expression and activity of these 
proteins are regulated by intracellular signaling molecules. Whereas many of these 
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kinases have specific small molecule inhibitors, delivery and toxicity concerns due to the 
need for large systemic doses preclude their use. 
The development of miR-based pharmaceuticals holds exciting promise for 
improving the status quo of medicine.13 Traditional pharmaceuticals have faced 
significant limitations: protein-based therapeutics are generally restricted to extracellular 
receptors; and small‐molecule drugs modulate only certain functions of their targeted 
protein and are limited in specificity. In contrast, by exploiting endogenous translational 
machinery by delivering synthetic miR mimics, genetic pathways can be regulated 
selectively.14 The range of miR-based pharmaceuticals is wide, with potential 
applications ranging from cancer to diabetes and heart failure. Furthermore, some miRs 
associated with cardiac development, endothelial cell proliferation, vascular integrity, 
and CM and vascular smooth muscle cell differentiation have been identified and could 
be applied as therapeutics.15-17 
While overexpressing anti-apoptotic proteins and antioxidants in CMs has shown 
functional improvements in animal models,18, 19 many delivery hurdles prevent clinical 
translation. The short circulation half-life of these proteins and small molecules20 
precludes systemic delivery due to the need for extended exposure to large amounts of 
therapeutics needed. To address this concern, many studies have been performed using 
biomaterials for sustained, local delivery.21, 22 Despite some successes, methods to 
deliver drugs to the infarct currently rely on passive release into the interstitium from 
delivery vehicles or internalization by phagocytic cells. As the majority of phagocyctic 
cells accumulate 24–72 hr following ischemia-reperfusion (IR) injury,23 delivery vehicles 
that rely on passive macrophage-mediated release do not inhibit the excessive 
apoptosis that occurs in CMs during the initial 72 hr. 
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Drug delivery vehicles that target CMs are virtually nonexistent, owing largely to 
the non- phagocytic nature of these cells. However, recent studies have implicated  
GlcNAc as a viable candidate for a drug delivery system targeted to CMs, demonstrating 
the ability of CMs to bind to and internalize GlcNAc-decorated liposomes.24, 25 
Challenges exist in the development of RNAi therapies, such as protecting the 
miR molecules from ribonucleases (RNases),14 and difficulty inducing cellular uptake by 
the target cell population. RNases that are present in bodily fluids readily degrade miR, 
requiring protective measures such as encapsulation of the miR26 or the use of 
chemically modified RNA.27 The highly charged backbone and size of nucleic acids 
precludes passive cell penetration,14, 28 necessitating incorporation of a mechanism for 
cellular uptake in most cell types. 
Solid particles have long been researched as delivery vehicles for bioactive 
molecules, to prevent delivery to unintended targets, convey therapeutic doses to tissue, 
and to shield cargo from recognition and degradation. However, the effects that spent 
vehicles or carrier degradation products may have on cells and tissue may disqualify the 
use of vehicles. Formulations of poly(lactic-co-glycolic acid) have been extensively used 
as micro-and nanoparticles, but degrade into acidic products that may elicit an 
inflammatory response.29 The recent development of polyketals as acid-degradable 
carriers provides a strategy for delivering therapeutics to cells and tissue where an 
inflammatory response would be undesirable;22, 29-32 for example PCADK degrades in 
acidic conditions—such as in the developing endosome—into acetone and 1,4-
cyclohexanedimethanol, both of which exhibit excellent biocompatibility. Already, 
polyketals have been shown to efficiently encapsulate small molecules and proteins, 
form micro- or nanoparticles, serve as extra- or intra-cellular delivery vehicles, and 
function compatibly in heart and lung applications.22, 29-32 
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Dendrimers, a class of radially symmetric, regularly branched polymers, have 
been extensively studied as delivery agents for a variety of drugs.33-35 One well studied 
dendrimer is poly(amido amine) (PAMAM), which generally consists of an 
ethylenediamine core that is reacted alternatively with methyl acrylate and 
ethylenediamine to form a size-tuned dendrimer commonly with amino termini.35 
Traditional strategies have largely consisted of physical entrapment of drugs within the 
relatively hydrophobic dendrimer core, with conjugated targeting moieties distributed 
among the dendrimer terminal groups. As such, dendrimers are attractive multi-
functional nanomaterials despite some side effects, such as cytotoxicity.36 Recent 
studies have extended dendrimer applications to siRNA- and miR- based therapeutics.35, 
37, 38 The suitability of a dendrimer-based RNAi therapeutic lies in part with the amino 
groups present at the termini and within the dendrimer that afford electrostatic 
interactions with—and thereby encapsulation and protection of—anionic miR mimics.37 
The terminal amines of many dendrimers can be readily conjugated with biomolecular 
ligands, which “decorate” the dendrimer with signals to potentially enhance cell targeting 
and uptake. Studies have indicated that varying the number of ligands on the vehicle 
surface elicits different binding and internalization kinetics, and dendrimeric materials 
can handily exert these “multivalent effects” by presenting an increased number, density, 
and arrangement of ligands.34, 38-40 The use of dendrimers for targeted miR delivery, 
however, is largely undeveloped, and novel architectures are needed that can bind 
sufficient amounts of miR with presenting adequate ligand density to trigger 
internalization. 
Until fairly recently, the heart was thought to be devoid of regenerative potential; 
endogenous mammalian cardiac regeneration declines rapidly after birth, but a small 
population of ckit+ cardiac-resident stem-like cells have been identified within the past 
decade.41 While not fully understood, researchers have induced the differentiation of 
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these CPCs into CMs, endothelial, and smooth muscle cells.42 These and other stem cell 
types have been attractive candidates for cell-based therapies wherein transplanted 
cells in the myocardium would differentiate and regenerate the damaged tissue. Results 
have been mixed: injected CPCs regenerated the myocardium and improved cardiac 
performance in rat and canine MI models;41, 43 and early human clinical trials 
demonstrated improved cardiac function resulting from injected stem cells,44, 45 although 
relatively few cells were retained within the myocardium, suggesting that regenerative or 
protective effects may occur through paracrine mechanisms rather than cardiogenesis. 
Studies have begun to explore stem cell-exerted paracrine effects: injection of 
conditioned media46, 47 or exosomes48 secreted from mesenchymal stem cells improved 
cardiac function and infarct size following IR. 
1.2 Specific Aims 
The need exists for therapeutic drug delivery systems that can mitigate tissue 
damage within and around the infarcted territory. Despite substantial development in the 
general field of nano-vehicles to deliver beneficial molecular cargo to cells, further 
research regarding vehicular architecture and targeting capabilities to suit delivery to 
cardiac-specific cells is needed. Furthermore, although stem cells are known to exert 
beneficial effects on the infarcted heart, the paracrine network of miR intercellular 
transfer from such cells has yet to be elucidated or exploited. We hypothesize that 
specially designed therapeutic systems will ameliorate the MI heart by featuring 
characteristics suitable for the delivery of cardio-protective and pro-regenerative agents. 
We propose investigation through the following aims: 
Specific Aim 1: Evaluate efficacy of a polymeric nanoparticle system featuring a 
surface-decorated carbohydrate ligand to enhance uptake by CMs. A molecular tether 
was synthesized to decorate PCADK nanoparticles with GlcNAc, a saccharide that 
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triggers internalization by otherwise non-phagocytic CMs. Functionalized nanoparticles 
(300-400 nm) loaded with anti-apoptotic p38 mitogen-activated protein kinase (MAPK) 
inhibitor SB239063 were injected into the myocardium directly following occlusion and 
reperfusion of the left descending coronary artery in a rat model of MI. The effectiveness 
of the proposed therapeutic system in mitigating cardiac dysfunction was determined by 
evaluation of CM apoptosis in infarcted tissue, ejection fraction, and infarct size. 
Specific Aim 2: Synthesize and validate novel dendrimeric vehicle featuring 
hemispheric-selective decoration of bioactive ligands for miR-based therapy. A vehicle 
design based on PAMAM architecture provided a platform to deliver therapeutic miR. It 
featured a region of one-half the structure devoted to nucleic acid binding and the other 
half to high-density ligand presentation that induced multivalent cell interactions. Human 
vascular endothelial cells (HUVECs) were treated with such “bowtie” structures loaded 
with the angiogenic miR-126 and decorated with poly(arginine)9 (poly(R)) or RGD 
peptides. Delivery system suitability was evaluated by quantifying cell proliferation and 
tube formation, two hallmarks of angiogenesis. 
Specific Aim 3: Evaluate cardioprotective/regenerative potential of exosomes 
secreted from hypoxic CPCs. The differential release of miR-containing RNA from CPCs 
subjected to hypoxia was evaluated by miR array and reviewed for pro-regenerative 
application. The protective/regenerative effects of the hypoxic exosomes were evaluated 
in relevant cardiac cells by evaluating angiogenic potential and mitigation of fibroblast 
stimulation. Furthermore, we employed statistical modeling (principle component (PC) 
and partial least squares regression (PLSR) analyses) to identify co-varying miRs and 








2.1 Myocardial infarction 
2.1.1 Statistics 
According to the American Heart Association,49 83.6 million Americans (>1 in 3) 
have at least one type of CVD. A major subgroup of coronary heart disease, MI, affects 
7.6 million Americans. Cardiovascular diseases accounted for 31.9% of US deaths in 
2010, which is more than any other major cause of death, and is greater than combined 
deaths from cancer and chronic lower pulmonary disease. In 2010, US direct and 
indirect costs of CVD totaled $315.4 billion, and costs are projected to increase to $918 
billion, when 43.9% of the US population is expected to have CVD. 
2.1.2 Pathogenesis 
Acute MI is most frequently a manifestation of coronary artery disease.50 It is 
commonly triggered by disruption of an atherosclerotic plaque in an epicardial coronary 
artery, which leads to clotting and occlusion of the artery. When unstable, plaques may 
also rupture and promote an occluding thrombus. Arterial occlusion prevents blood from 
flowing to part of the heart, and muscle is injured due to the resulting ischemia, or lack of 
oxygen and nutrients. Injured heart tissue conducts electrical impulses more slowly than 
healthy tissue, creating a difference in conductance velocity and leading to lethal 
arrhythmias. Symptoms of MI include pain in the chest, upper extremity, and jaw, as well 
as shortness of breath, excessive sweating, nausea, or fainting. However, these 
symptoms are not specific to MI, and proper diagnosis may include evaluation by 
echocardiogram (ECG), biomarkers, and cardiac imaging.51 
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2.1.3 Diagnosis 
Diagnosis criteria for acute MI includes detection of increased levels of 
biomarkers (such as tryponin or creatine kinase) with symptoms of ischemia, changes in 
ECG readout including development of pathological Q waves, or imaging evidence of 
loss of viable myocardium.51 The term MI may include qualifiers, such as the amount of 
myocardial loss (infarct size), circumstances that lead to the infarct (whether 
spontaneous or medical procedure-related), and the timing of the necrosis and 
observation (evolving, healing, or healed).52 Immediate treatments for suspected MI 
include aspirin to prevent further blood clotting, and nitroglycerin to treat chest pain. 
Some immediate treatment regimens include oxygen, but that has been shown to be 
deleterious to the heart. Reperfusion therapy includes angioplasty and thrombolysis, and 
multiple blockages may require coronary artery bypass graft surgery (CABG). There are 
no definitive treatments for MI to repair or regenerate the heart.51 
2.1.4 Pathophysiology 
The pathology of MI includes myocardial cell death due to ischemia, either 
through oncosis (ischemic cell death) or apoptosis. After the onset of MI, cell death is not 
immediate but takes a period of time to develop (as little as 20 min). Complete necrosis 
of the affected myocardial cells takes several hours, and is a function of collateral 
circulation to the to the ischemic zone, arterial occlusion, sensitivity of myocytes to 
ischemia, pre-conditioning of cells, and individual demand of cells for oxygen and 
nutrients. The size of MI can be classified as microscopic, small (<10% of left ventricle 
(LV) myocardium), moderate (10-30% of LV), or large (>30% of LV).51 
The stages of MI are acute, healing, or healed. In acute MI, affected myocardium 
features the presence of polymorphonuclear leukocytes. The absence of 
polymorphonuclear leukocytes, and presence of mononuclear cells and fibroblasts 
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characterize the healing infarction. The healed infarction features scar tissue without 
cellular infiltration. The temporal characterization of MI may be classified as evolving (<6 
hr), acute (6 hr – 7 days), healing (7 days – 28 days), and healed (29 days and 
beyond).52 
2.1.5 Biomarkers 
A preferred method for diagnosis includes detection of biomarkers in the 
circulation, as myocardial cell death increases the appearance of different proteins in the 
blood, such as myoglobin, troponin (I and T), creatine kinase (CKMB) and others.52 
However, an increase in such biomarkers reflects necrosis, and not necessarily acute MI. 
Other conditions that may raise biomarkers include congestive heart failure, aortic 
dissection, aortic valve disease, hypertrophic cardiomyopathy, renal failure, stroke, 
sepsis, extreme exertion, and burns.53, 54 As troponin is nearly absolutely specific to 
myocardial tissue and exhibits high clinical sensitivity, it is the preferred biomarker for 
myocardial necrosis. Its sensitivity can reflect even microscopic zones of myocardial 
necrosis.55 
2.1.6 Imaging techniques 
Imaging techniques allow for great evaluation and characterization of MI. 
Important parameters include perfusion, myocyte viability, myocardial thickness, motion, 
and effects of fibrosis on kinetics of radiolabelled and paramagnetic contrast agents. 
Commonly used imaging techniques include echocardiography,56 radionuclide 
ventriculography,57 myocardial perfusion scintigraphy, and magnetic resonance 
imaging.58 Positron emission tomography and X-ray computed tomography are less 
commonly used.59, 60 
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2.1.7 Risk factors and recurrence prevention 
Risk factors for acute MI include existing CVD, age, tobacco smoking, high low-
density lipoprotein blood levels, low high-density lipoprotein levels, diabetes, high blood 
pressure, lack of physical activity, obesity, chronic kidney disease, and excessive 
alcohol consumption.55 The risk of MI recurrence includes strict blood pressure 
management, ceasing tobacco smoking, exercise, healthy diet, and limitation of alcohol 
intake. Medications for recurrence prevention include antiplatelets (such as aspirin), beta 
blockers, angiotensin-converting enzyme (ACE) inhibitors, statin therapy, aldosterone 
antagonists, and heparin. 
2.2 pH-Sensitive polymers 
2.2.1 Polymers for drug delivery 
The decreasing pH of the maturing endosome provides for two strategies by 
which the endosome can be disrupted: hydrolysis and protonation.33 In the first camp are 
acetal and orthoester hydrolysis (Figure 2.1). In use, these functional groups link two 
molecules together (such as polyethylene glycol (PEG) to increase water solubility and a 
hydrophobic molecule), which provides for convenient characteristics for the overall 
compound. As the endosomal pH decreases, the acetal or orthoester linker is cleaved, 
creating a scenario where the endosomal membrane is disturbed, such as a 










Protonation of the primary amines in polyethylenimine (PEI) (Figure 2.2), as well 
as imidazole and carboxyl groups, is the other general strategy to disrupt the endosome. 
The mechanism by which the first two approaches work is described by the “proton 
sponge” hypothesis.33 That is, that only a percentage of these groups are protonated at 
physiological pH, and that as the endosome becomes more acidic, the amines and 
imidazoles act as a buffer by binding to the incoming hydrogen ions. The ATPase 
enzyme, which actively transports protons into the endosome from the cytosol, then 
transports more hydrogen ions in order to reach lysosomal pH. However, an influx of 
counter ions ensues to balance the increased number of protons. It is this increased ion 
concentration which leads to osmotic pressure in the endosome, and ultimately swelling 
and rupturing of the endosomal membrane. As every third atom of PEI is nitrogen, there 
is a high density of amines, only 15-20% of which are protonated at physiological pH 
(the pKa of primary amines in PEI is ~5.5). Polyethylenimine is commercially available 
and was an early method for gene delivery, but the cytotoxicity of PEI limits its use, 










Imidazole protonation (Figure 2.3) relies on the “proton sponge” theory, yet it is 
significantly less cytotoxic than PEI.61 The pKa of imidazole is ~6.0, providing an 









The third major approach to endosomal disruption by protonation is carboxyl 
protonation (Figure 2.4), which converts an overall hydrophilic polymer into a 
hydrophobic polymer.62 In this scenario, hydrophobic molecules are conjugated to a 
polymer that also includes carboxyl groups, some of which remain unprotonated at 
physiological pH. Examples of such polymers include polyethylacrylic acid (PEAAc) and 
polypropylacrylic acid (PPAAc).62, 63 As the pH drops in the maturing endosome, the 
number of protonated carboxyl groups increases, leading to the conformation change of 
the polymer. This causes the hydrophobic tails of the polymer to partition into and 










2.2.2 Acid-cleavable acetal and orthoester bonds 
Use of therapeutic-loaded liposomes as a method of cytoplasmic drug delivery 
has been studied extensively for the past 30 years.64, 65 Upon internalization by 
endocytosis, the destabilization of pH-sensitive liposomes in the acidic endosome and 
redistribution of the bilayer components leads to destabilization of the endosomal 
membrane. This allows for the contents of the liposome to leak into the cytoplasm. 
Alternatively, lipids can be used to create lipoplexes. Of the several types of lipid pH-
sensitivity, acetal and orthoester linkages will be discussed. 
Acetals can be synthesized from primary, secondary, and tertiary alcohols.65, 66 
The rate of hydrolysis is first order relative to the hydronium ion. Therefore, per unit 
decrease in pH, the rate of hydrolysis increases ten times. It is worth noting that the rate 
of hydrolysis can be tuned according to the structure of the acetal, something which can 
be useful for temporal control of hydrolysis in the maturing endosome.67 
Unlike phospholipids, glycolipids (Figure 2.5) are not usually charged, which can 
ease synthesis and removes the potential for ionic interaction with the biological 
system.68, 69 Additionally, the hydroxyl groups on the sugar group allows for surface 
modification. Song, et al. synthesized a glycolipid conjugate of glucose and two palmitoyl 










However, the researchers found that the acetal hydrolyzed rapidly at pH 4, but 
relatively slowly at pHs 5 to 7. The fact that only late endosomes and lysosomes reach 
an adequately low pH indicates that this lipid may not be a strong candidate for drug 
delivery. 
In another approach, Wong, et al. included the acid-labile acetal linkage in their 
synthesis of a PEG lipid, which they used as a lipopolyplex to deliver DNA.71 They 
included a cationic group because previous research has indicated that such groups can 
interact with anionic cell surface receptors and enhance the endosomal release rate of 
drugs. The presence of PEG can shield the cation from interaction with other 










That the acetal linker of lipids of similar structures hydrolyzes as varying pHs 
provides means by which drug delivery can be tailored depending on the progression of 
endosomal maturation.  
Orthoesters are known to be one of the most acid-sensitive functional groups, 
and due to a stable reaction intermediate, are generally expected to hydrolyze more 
quickly than acetals in response to a decrease in pH.72 Hydrolysis of the orthoester in a 
lipid cleaves the headgroup, leading to the collapse of the liposome and release of its 
contents. 










Liposomes including this lipid demonstrated the ability to encapsulate and then—
in 10 min at pH 3.5—release fluorescent molecules. To fully cleave the headgroup, the 
mechanism undergoes two fast hydrolysis steps of the orthoester, but complete 
fragmentation of the lipid requires the slow final step of hydrolysis in the cleavage of an 
ester group. Incorporation of a single orthoester functional group in a lipid for drug 
delivery then may be most appropriate for collapse of the liposome in a mature 
endosome. 
To promote faster cleavage of the headgroup, Guo et al. designed a lipid that 
incorporated a diorthoester functional group.69, 74 The benefit of this approach is that the 
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fast first step of hydrolysis of the diorthoester completely fragments the lipid, leading to 





Figure 2.8. Synthetic scheme for preparation of a pH-sensitive PEGylated lipid. Consists of 
a distearoyl gylcerol hydrophobic tail conjugated to a PEG headgroup through a diortho ester 
linkage. Liposomes composed partially of this lipid demonstrated long circulation times and acid-
triggerable content release. Especially useful is the diorthoester linkage, which leads to cleavage 




This lipid was found to be stable in pH 7.4 buffer at 37oC, but degraded in pH 5 
within one hour. In a mild pH of 5.5, liposomes (10% lipid content were degradable) 
released most of their contents within 30 min. 
2.2.3 Multi-functional polymeric drug delivery systems 
In an effort to more closely mimic naturally occurring viruses and endosomal-
disrupting toxins, researches have sought to design multifunction carriers which include 
three primary functions: targeting for endocytosis; disrupting the endosome by a 
triggered pH-responsive element; and delivering active therapeutic agents after 
trafficking into the cytoplasm.66 
Murthy et al. developed one of the first designs of such multifunction polymeric 
carriers, termed “encrypted polymers”.75, 76 In this approach (Figure 2.9), the polymer 
contains a membrane-disruptive backbone connected to the other molecular species via 
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acid labile acetal linkers. A disulfide bond connects the acid-degradable linker to either 
PEG grafts or therapeutic molecule. A targeting ligand for endocytosis can be attached 
to the PEG chains. In cases where the drug is not conjugated via a disulfide bond, ionic 










In the whole polymeric configuration, PEG chains “mask” the membrane 
disruptive potential of the backbone. However, once the pH of the maturing endosome 
drops, hydrolysis of the acid-degradable linker “unmasks” the backbone and allows it to 
disrupt the endosome, and the drug diffuses into the cytoplasm. Within the cytoplasm, 
disulfide bonds are reduced, and the active therapeutic molecule is free to perform its 
intracellular function. 
Knorr et al. built on existing strategies and developed another approach for 
intracellular DNA delivery.77 Historically, polyplexes of negatively charged DNA and 
positively charged polymers have been developed as a way to shield DNA from 
degradation in the endosome. Polyethylenimine (PEI) is a good choice due to its high 
proton buffering capacity. In order to achieve high gene transfer activity, an excess of 
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PEI is used, which abundance leads to a net positive charge of the polyplex. This can be 
detrimental due to interactions with negatively charged physiological compounds. It is 
possible to alleviate these side affects by neutralizing the polyplex surface by 
incorporating PEG chains in the formulation. The Knorr group used Buchwald-Hartig 
coupling to substitute a PEGylated aromatic bromine with piperazine (Figure 2.10). The 
remaining secondary amine of piperazine then reacted with an ester-maleimide 






Figure 2.10. Scheme involving Buchwald-Hartig coupling for synthesis of a PEI polyplex. 
Substitution of a PEGylated aromatic bromine with a protected piperazine, followed by generation 
of an aniline-type acetal for acid-labile cleavage. PEI forms a polyplex with DNA, which surface is 




The acetal link between PEG and the compound has a purpose. Extensive 
PEGylation of polyplexes reduces the intracellular release of DNA from the endosome. 
Therefore, as the pH drops, the polyplex becomes less PEGylated and results indicate 
higher gene transfer efficiency from these de-PEGylated polyplexes than their non-acid 
labile counterparts.77 
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2.3 Peptide- and saccharide-conjugated dendrimers for targeted drug delivery 
Dendrimers provide a unique scaffold for biological applications because of their 
size, multivalency, and well-defined chemical composition.34 Dendrimeric conjugates 
containing multiples copies of saccharides or peptides may themselves exhibit 
therapeutic benefits and be developed as anti-prion, anti-microbial, and anti-viral agents. 
Positively charged dendrimers, due to either native PAMAM terminal amines or 
guanidine-modification, have shown the ability to prevent prion folding and even induce 
prion unfolding,78 with decreased cytotoxicity due to dendrimer glycosylation.79 For anti-
microbial application, dendrimers modified with largely positive peptides show strong 
toxicity and selectivity for bacteria.80 Glycodendrimers have demonstrated anti-viral 
properties by presenting saccharides to either directly bind to viruses or to saturate cell 
surface receptors;81 both methods inhibit virus-cell interaction. In other applications, 
dendrimers can be used to modify other nanodevices, such as carbon nanotubes,82-84 
gold nanoparticles85 and nanorods,86 magnetic particles,87, 88 and quantum dots.89 
Modification by dendrimers serves to improve biocompatibility, enhance solubility, and 
provide a mechanism for tissue- or cell-specific targeting. 
As illustrated in Figure 2.11, there are in general three methods to load the 
dendrimer scaffolds with therapeutics. First, therapeutic compounds may associate with 
dendrimers through hydrophobic interactions, either by inclusion within the dendrimer or 
the hydrophobic pit of dendrimer-bound cyclodextrin. This method has provided for the 
solubilization of a huge range of hydrophobic small molecules involved in anti-cancer, -
depressant, -inflammatory, and -microbial applications.90-92 The second association is 
through electrostatic interaction: charged therapeutics can directly form complexes with 
dendrimers containing counter-charged groups. This method has been widely studied for 
nucleic acid-based therapeutics. The third approach is through covalent bonding, which 
method is convenient is convenient when the therapeutic contains functional groups that 
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are readily ligated. This can be beneficial to prevent hydrophilic molecules from leaching 
out of dendrimer and inducing side interactions. In the case where a therapeutic agent 
should be free from vehicle to be fully active, consideration should be taken for how the 
agent will be released, such as by conjugation via acid labile linkage that can be cleaved 
in the mature endosome. Covalently attaching molecules to dendrimers is also of use in 
the development of drug delivery vehicles, as bound fluorophores can elucidate vehicle 





Figure 2.11. Different types of dendrimer–therapeutic cargo associations. (a) Hydrophobic 
interactions between drug molecules and dendrimer backbone or constituent. (b) Ionic binding. 
(c) Covalent ligation, including degradable linkages. (d) Dendrimers can also be used to 





2.3.1 Cell- and tissue-targeting of bioactive dendrimer conjugates 
The short peptide RGD is known to bind to integrins,93 and studies have 
indicated that cyclized RGD peptides bound with high affinity to cells expressing the aVb3 
integrin, such as angiogenic tumor endothelial cells. By decorating the surface of 
generation 5 PAMAM dendrimers with a double cyclized RGD peptide and Alexa Fluor 
488, Baker’s group showed preferential binding of the dendrimer to HUVECs, and some 
binding to Jurkat T lymphocyte cells in vitro.94 In contrast, the dendrimers showed only 
moderate binding to KB cells and virtually no binding to L1210 mouse lymphocyte cells. 
This strategy for anti-tumor therapy would rely on targeting the tumor vasculature to 
inhibit neovascularization.  
Other groups have applied cyclized RGD in dendrimeric delivery systems. 
Liskamp’s group conjugated 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA) to a dendrimer featuring multivalent cyclic-RGD to develop a vehicle that could 
target and image tumors.95 Following complexation of targeted vehicle with 111In and in 
vitro validation of binding to aVb3 integrin, the group injected the radiolabeled dendrimer 
into SK-RC-52 tumor-bearing mice and found enahanced uptake of the RGD-targeted 
vehicle in tumors. Their analysis on the effect of multivalency indicated that tetrameric 
RGD-dendrimer exhibited better tumor targeting than dendrimers decorated with two or 
fewer RGD peptides. Development of a targeted delivery vehicle that chelates 
radioisotopes could provide a pathway for tumor therapy by complexing DOTA-
conjugated glycodendrimers with 90Y3+. However in other studies, dendrimers conjugated 
to Gd(III)-chelating agents and cyclized RGD demonstrated effective binding to 
melanoma cells only in vitro, while in vivo tumor uptake was negligible.96 The inability for 
vehicle to extravasate into tumor illustrates that RGD may be a ligand more suited for 
targeting tumor vasculature rather than tumor cells. 
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While most bioactive dendrimer conjugates rely on surface functionalization, 
Hammond’s group ligated a clinically relevant anti-tumor peptide tryptophan-isoleucine-
phenylalanine-tryptophan-isoleucine-glutamine-leucine (WIFPWIQL) for gene therapy.97 
This was accomplished by reducing the disulfide bond of a generation 4 cystamine-core 
PAMAM dendrimer, followed by conjugation to the peptide through a heterobifunctional 
linker. This vehicle showed propensity to condense plasmid DNA into small structures 
(<210 nm) and transfected prostate carcinoma cells in vitro to express luciferase. The 
group demonstrated up to 5x greater transfection with this asymmetrical vehicle than 
control groups, and even greater transfection than PEI, a transfection standard. 
Liu et al. performed in vivo phage display to identify peptide sequences that 
targeted lung cancer xenografts in a mouse model.98 After conjugating generation 4 
PAMAM dendrimers with fluorescein isothiocyanate (FITC) and the phage display-
identified targeting sequence arginine-cysteine-proline-leucine-serine-histadine-serine-
leucine-isoleucine-cysteine-tyrosine (RCPLSHSLICY), the group found that the particles 
enriched three times more in NCI-460 than 293T cells in a time- and dose-dependent 
manner. In vivo, the group injected the same vehicles intravenously for biodistribution 
assay, and found that while the targeting and non-targeting vehicles were both found in 
other organs, animals treated with targeting vehicles exhibited 30% greater fluorescence 
intensity in the lung cancer xenograft than non-targeting vehicles.  
Another research group investigated the use of a previously identified peptide 
cysteine-arginine-glutamic acid-lysine-alanine (CREKA) for use in a dendritic tumor-
targeting vehicle.99 In vivo phage display had demonstrated its ability to home to tumor 
extracellular matrix via recognition of blood clotting and in a separate study, was used 
for atherosclerotic plaque imaging. In addition to CREKA, the group also investigated the 
use of a cyclic nonapeptide, LyP-1 (cysteine-glycine-asparagine-lysine-arginine-
threonine-arginine-glycine-cysteine) that recognizes tumor lymphatic cells. By tethering 
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these peptides and fluorescein to a pentavalent dendritic scaffold, the ability of these 
peptides to target tumors was elucidated: they found that CREKA-functionalized 
dendrimers localized in prostate cancer xenograft vasculature, thereby justifying the use 
of CREKA-functionalized dendrimers for the use of future cancer therapies through anti-
vasculature means.  
Besides phage display, another method for the development of a targeting 
dendrimer is through derivation of peptide sequences from known targeting proteins. 
Leptin is a 146 amino acide polypeptide that is secreted into the bloodstream by 
adipocytes and acts on leptin receptor-expressing cells in the brain, and Barrett et al. 
identified leptin30, a 30-amino acid derivative of the leptin polypeptide that localized in 
the parenchyma.100 By conjugating a poly-L-lysine dendrimer with leptin30, Jiang’s group 
demonstrated the ability of the dendrimer to traverse a brain capillary endothelial cell 
monolayer and then transfected brain cells with the targeting dendrimers.101 This was 
followed by effective in vitro transfection of BV-2 microglial cells by luciferase plasmid 
DNA-loaded dendrimers and in vivo accumulation of the dendrimers in the brain of a 
mouse model. Luciferase activity in the brain was in 80% greater abundance in the 
targeting dendrimer group than the non-targeting dendrimer group, thus demonstrating 
the use of leptin30-decorated dendrimers for gene therapy to the brain. 
Macrophages exhibit a receptor for mannose, so in an effort to develop a 
macrophage-targeting dendrimer, Benito, et al. conjugated mannose and b-cyclodextrin 
to dendrimers, followed by inclusion of fluorescent 6-p-toluidino-2-naphthalenesulfonic 
acid within the cyclodextran.102 The group explored the multivalent effect of vehicle 
activity by varying level of decoration from one to six mannose molecules and found an 
amplification of lectin-binding strength for the dendrimers with higher valance, 
demonstrating the “cluster effect.” Such a delivery vehicle could be useful in therapies to 
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target macrophages, such as rheumatoid arthritis and other macrophage-mediated 
disorders. 
In addition to applicability of mannosylated dendrimers to macrophages, 
Uekama’s group demonstrated gene transfer via these dendrimers in other cell types.103 
They found that mannosylated generation 3 dendrimers, complexed with luciferase 
pDNA, provided for high gene transfer activity in NR8383, NIH3T3, HepG2, and 
especially A549 cells. Interestingly, the group found that gene transfer activity of this 
glycodendrimer was not inhibited by the presence of serum in the treatment medium and 
described the ability of the vehicle to escape the endosome and localize to the nucleus. 
These results indicate that mannosylated dendrimer could provide for effective gene 
transfer therapy in various cell types. 
Carbon nanotubes have great potential for biomedical applications, but can 
exhibit cytotoxicity. Bertozzi’s group employed copper-mediated click chemistry to 
conjugate generation 3 glycodendrimers (mannose, lactose, galactose) to single-walled 
carbon nanotubes and found dramatically decreased cytotoxicity in HEK293 cells.104 
Furthermore, decoration of SWCNTs with glycodendrimers increased solubility up to a 
few months. In vitro studies with FITC-conjugated dendrimers demonstrated that these 
decorated SWCNTs showed selectivity in binding to lectins Conavalia ensiformis 
agglutinin, Arachis hipogaea agglutinin, and Psophocarpus tetragonolobus agglutinin.  
Hepatic cells express asialoglycoprotein receptors that bind galactose and N-
acetylgalactosamine (GalNAc), which receptors have been exploited for treatment of 
hepatic cancer with drug-loaded dendrimers. Medina, et al. GalNAc to generation 5 
PAMAM dendrimers with a diaminobutane core105 that had been shown to preferentially 
accumulate in the liver and extravasate through the leaky tumor vasculature.106, 107 
Through in vitro studies of HepG2 and MCF-7 cells, the group found selective uptake by 
hepatic cells, with nearly 100% of the HepG2 cells internalizing the dendrimers within a 
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short period of time. A benefit of this delivery system was that the vehicle required only 
12 molecules of saccharide per dendrimer to trigger uptake. Nearly 90% of the terminal 
groups remain for conjugation to anti-tumor drugs or imaging moieties. 
Asialoglycoprotein receptors on hepatic cells have been targeted for RNAi 
therapy with gene-loaded dendrimers. Following successful development of a charge 
neutral, hepatic cell-targeting delivery vehicle, Luo’s group complexed anti-luciferase 
siRNA to hydrazide-terminated PAMAM at pH 5 via electrostatic interaction.108 The 
remaining amines were crosslinked to retain encapsulated siRNA following pH 
neutralization. This loaded GalNAc-conjugated dendrimer successfully induced RNAi by 
reducing fluorescence in luciferase-expressing HepG2 cells in vitro. This demonstrated 
the potential for charge-neutral dendrimeric vehicles in drug-delivery applications where 
cytotoxic effects due to dendrimer cationic charge are detrimental. 
2.3.2 Delivery of bioactive dendrimer conjugates carrying therapeutics 
As a cell-penetrating peptide, glycine-arginine-lysine-lysine-arginine-arginine-
glutamine-arginine-arginine-arginine-proline-glutamine (Tat)-decorated dendrimers have 
seen varied success as transfection agents. In an early paper by Juliano’s group, 
generation 5 PAMAM dendrimers conjugated to Tat (15.9 peptides per dendrimer) 
showed no improvement in the delivery efficiency of siRNA oligonucleotides against the 
transmembrane protein p-glycoprotein MDR1 in 3T3 cells.37 In a more recent paper, 
however, Chang’s group found that Tat-functionalized dendrimers exhibited high 
transfection levels of anti- epidermal growth factor receptor (EGFR) psiRNA;109 in fact, 
they demonstrated that the targeted dendrimer performed as well as the Lipofectamine 
2000 treatment group. In vitro, EGFR knockdown in U251 glioma cells by the targeting 
dendrimer was slightly better than lipofectamine, whereas apoptosis was similar 
between the treatment groups. Furthermore, in vitro cell invasion was inhibited to a 
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greater degree by the targeted delivery vehicle than lipofectamine (66.0% versus 62.3%). 
In a U251 subcutaneous tumor mouse model, the group described significant apoptosis 
and depressed EGFR expression by the targeted vehicle, and that the tumor volume 
increased by only 15x whereas saline treated animals experience 89-fold increase. 
Following passive localization due to the enhanced permeability and retention effect of 
tumors, cell-penetrating peptides such as Tat can be used for anti-tumor therapies. 
Another peptide derivative with great potential for targeting the brain is Agniopep-
2. Part of the Kunitz domain of aprotinin, this 19-amino acid peptide accumulates in the 
parenchyma, binds to lipoprotein receptor-related protein 1, and exhibits a high 
propensity to transcytose across the blood-brain barrier.110 Jiang’s group conjugated 
Angiopep-2 to the terminal groups of generation 5 PAMAM and determined that the 
vehicle was internalized by brain capillary endothelial cells through clathrin and 
caveolae-mediated endocytosis, and to a small extent, macropinocytosis.111 The group 
found in a mouse model that brain uptake of targeting vehicles loaded with fluorescent-
labeled DNA was up to 8-fold greater than non-targeting vehicle, and determined a 
positive correlation between the level of dendrimer decoration and brain uptake. In a 
later study, the group found the biodistribution of the targeting vehicle in the brain—
especially within the tumor—was greater than controls and demonstrated the ability of 
Angiopep-2 modified dendrimer to target glioma.112 Furthermore, they loaded the 
dendrimers with tumor necrosis factor (TNF)-related apoptosis-inducing factor (TRAIL) 
and in a glial xenograft mouse model, found greater apoptosis in the tumors due to 
targeting dendrimer treatment groups than controls, including commercial Temozolomide. 
In survival studies, the targeting dendrimer increased mean survival time significantly: 61 
days for Angiopep-2-modified dendrimer versus 49 and 25 days for Temozolomide and 
saline treatment groups. These results that the targeted delivery vehicle can perform 
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better than a clinical standard are promising for future applications in treating brain 
tumors. 
Colchicine is a current standard treatment to treat gout, but has potential as an 
anti-cancer agent due to its inhibition of mitosis. In an attempt to develop a targeted 
vehicle for colchicine to cancer cells, Reymond’s group conjugated the drug to 
dendrimers via a thioether bond and screened a small collection of attached glycans 
(glucose, galactose, GalNAc, and lactose) and amino acids (including serine, threonine, 
histidine, aspartic acid, glutamic acid, leucine, valine, and phenylalanine) for uptake by 
HeLa tumor cells.113, 114 Although the decorated dendrimers reduced activity of the drug, 
the group found that all glycodendrimeric vehicles caused extensive in vitro HeLa cell 
death. Conversely, non-transformed mouse embryonic fibroblasts experienced extensive 
cell death only from treatment with highly GalNAc-decorated vehicles, and not other 
glycodendrimer treatments. These findings suggest that several saccharides may serve 
as effective ligands for selective anti-tumor dendrimeric delivery vehicles while not 
targeting other cell types; glucose-conjugated dendrimers demonstrated a high 
selectivity for HeLa cells by inducing cell death in 163-fold more HeLa cells than 
fibroblasts. It should be noted that, whereas many dendritic vehicles are based on 
branched polymers, the structure of Reynold’s dendrimers consisted solely of amino 
acids. Their reasoning was based on the aspect that unless the vehicle is cleared from 
the body, dendritic drug carriers should undergo intracellular biodegradation after 
delivery, and that a dendrimer consisting of peptide building blocks could prove more 
biocompatible than other dendrimers. 
One group used galactose-conjugated dendrimers as a delivery vehicle for anti-
malarial therapy.115, 116 Primaquine is a common anti-malarial medication, but in regular 
formulation can exhibit severe side effects, such as hemolysis. To target the drug to the 
site of metabolism in the liver and shield it from inducing side effects in side cell 
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populations, the researchers conjugated galactose to polypropyleneimine dendrimers 
and complexed primaquine within the carrier via the hydrophobic effect. Two hours after 
IV injection of the loaded vehicle, 50% of the initial dose was found in the liver, 
compared to 26% of the non-targeted vehicle, demonstrating the targeting ability of 
galactose. Besides targeting to the liver, coating of the dendrimer with galactose had 
three beneficial effects: prolonged drug release up to 6 days, compared to 2 days for 
uncoated dendrimer; 15-fold greater entrapment of primaquine; and drastically reduced 
hemolysis due to surface neutralization by glycosylation. In a later paper, the group 
loaded a related anti-malarial drug, chloroquine, into galactose-decorated poly-L-lysine 
dendrimers and found five-fold decreased uptake of the vehicle by macrophages than 
uncoated dendrimers.115 This characteristic would allow for shielding of the delivery 
system from macrophages while targeting the liver. Similar to previous findings, coating 
of the lysine dendrimers with galactose reduced hemolytic toxicity and immunogenicity of 
the conjugates while extending the release of the anti-malarial drug. 
Significant proof-of-principle research has been conducted with peptide- and 
glycodendrimer, i.e. the majority of research articles describe uptake of fluorophore-
conjugated dendrimers, while relatively few articles demonstrate therapeutic effects of 
drug-loaded vehicles. Obviously, for proposed drug delivery vehicles to reach the clinic 
this next step of testing must be taken. It is difficult to directly compare peptide—versus 
saccharide—decorated dendrimers, but it is clear that if specificity in vehicle uptake is 
desired, then appropriate ligands for cell-material interactions must be identified. The 
ready availability of phage display allows for screening of a much larger number of 
potential peptidic ligands than the number of ligands generally screened in glyco-
libraries. Considering the drastically greater number of permutations available in 
oligosaccharides than in peptides (206 versus 1.44*1015 in hexanucleotides and 
hexasaccharides, respectively),117 potential exists for identification of more efficient 
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saccharide ligands. Glycan arrays exist that can identify glycans that bind to peptides118, 
119, but methods should be adapted for binding to cells. The status quo in the 
development of dendrimeric delivery vehicles relies heavily on phage display and 
screening of small saccharide libraries for ligand identification, and to a small extent, 
derivation of short peptidic ligands from much larger antibodies and other binding 
proteins. Future development could include these methods and screening of 
glycosylated peptides and larger saccharide libraries. 
2.4 Therapeutic potential of exosomes 
Exosomes are small membrane-bound vesicles (30 – 120 nm) of endocytic origin 
and are actively secreted from cells. They are derived from luminal membranes of 
multivesicular bodies and are constitutively released by fusion of multivesicular bodies 
with the cell membrane.120 They are loaded with a variety of bio-active molecules—
including mRNA, miR, and proteins—that may change based on normal or pathological 
conditions. Originally considered cell debris or to contain cell refuse, membrane-derived 
vesicles were more appropriately characterized in 1987,121 and cell-cell information 
transfer via exosomes observed in 2002,122, 123 but miR encapsulation by exosomes was 
not verified until 2007.124, 125 Interestingly, the miR signatures are unique among the 
different carriers,126 and even between carriers and parent cells, suggesting regulated 
export of miRs.126-128 In the past few years, research results have suggested that 
exosomes can mediate cellular, tissue, and organ level communication under normal 
and pathological conditions. 
2.4.1 Exosome-cell interactions 
Once released, exosomes can interact with neighboring cells or enter the 
circulation, and have demonstrated the ability to cross the blood-brain barrier.129, 130 
Upon interaction with recipient cells, they may bind with plasma membrane via specific 
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receptors or be internalized by micropinocytosis to fuse with the plasma membrane, or 
be internalized by distinct endocytosis.131, 132 Exosomes have been shown to mediate in 
a wide range of functions, including tumor progression by promoting angiogenesis, 
tumor metastasis, acting as antigen-presenting vesicles to stimulate the anti-tumoral 
response, disseminate Alzheimer pathology, and have been implicated in the activities of 
stem cells.120 
2.4.2 Useful properties 
Several properties of exosomes make them especially suitable for ex vivo study 
and manipulation, and potentially useful in cell-cell communication.120 Exosomes have 
unique protein and miR signatures, which may differ from the parent cell. They exhibit 
specific biophysical properties, such as size and density that enable isolation/separation 
(such as by centrifugation).133 Their rigid lipid membrane retains structural integrity 
through freezing and thawing, as well as rendering them insensitive to hypotonic 
bursting.133, 134 Exosomes exhibit cell-specific signaling and targeting ligands. Finally, 
they are capable of acting as vehicles for drug delivery because of their ease of being 
isolated, and their potential for manipulation of RNA and protein content.129 
2.4.3 Exosomes in the heart 
Myocardial tissue secretes exosomes, which may be involved in heterocellular 
communication in the adult heart.135 Telocytes have been observed to secrete them in 
the border zone of the post-infarct heart.136 Barile et al. provided ultrastructural evidence 
that exosomes are secreted by cardiac progenitor in the normal adult mouse heart, and 
provided evidence of exosome uptake by CMs.135 Furthermore, Losordo’s group 
investigated exosome secretion from human and mouse hearts and provided electron 
microscopic images exosomes being formed within LV CMs from both healthy and heart 
failure patients.137 Barile, et al. went on to show multivesicular bodies in CPCs, 
 31 
suggesting that CPCs also generate exosomes.135 Other researchers have observed 
exosomes in intracellular space between sarcomere, t-tubule, and nucleus after 
coronary artery.138 While it is still unknown how cardiac cells internalize exosomes, 
evidence points to the active internalization, rather than nonspecific membrane fusion, of 
exosomes.135, 139 Direct internalization and active transport of exosomes via the 
endocytic pathway to the perinuclear region has been shown, and Barile, et al. observed 
their uptake within small, cytoplasmic structures.135 The therapeutic benefit of CPC 
exosomes have been briefly explored: they have been shown the enhance endothelial 










Myocardial infarction affects 985,000 new patients in the U.S. annually and is the 
leading cause of global morbidity and mortality.142 During ischemic injury and in 
subsequent reperfusion,143 apoptotic signaling cascades in CMs are triggered, leading to 
localized death at the cellular level.144 As adult CMs are terminally differentiated145, 146 
and relatively non-proliferative,147 the ischemic insult leads to eventual dysfunction and 
failure at the organ level.6, 148 Because the initial cell death is primarily regional,7 
localized therapy to target and reverse the damage to the injured myocardium is quite 
promising. Therefore, CM-specific rescue presents itself as a compelling therapeutic 
target following MI.  
Apoptotic pathways are complex and include many molecules, including whose 
activation either promote or inhibit cell death. Several proteins in these pathways have 
demonstrated a cardioprotective role, such as Bcl-2,8, 149 Bcl-xL,10 and XIAP.11 Other 
proteins outside of apoptotic pathways also improve cell survival, such as SOD and 
Catalase that attenuate oxidative stress produced during IR injury.12, 150 Furthermore, 
expression and activity of these proteins are regulated by intracellular signaling 
molecules such as JNK,151, 152 Akt153 and p38.154 Whereas many of these kinases have 
specific small molecule inhibitors, delivery and toxicity concerns due to the need for 
large systemic doses preclude their use. 
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While overexpressing anti-apoptotic proteins and antioxidants in CMs has shown 
functional improvements in animal models,18, 19, 155-157 many delivery hurdles prevent 
clinical translation. The short circulation half-life of these proteins and small molecules20 
precludes systemic delivery due to the need for extended exposure to large amounts of 
therapeutic needed. To address this concern, many studies have been performed using 
biomaterials for sustained, local delivery.21, 22, 30-32 Despite some successes, methods to 
deliver drugs to the infarct currently rely on passive release into the interstitium from 
delivery vehicles or internalization by phagocytic cells. As the majority of phagocyctic 
cells accumulate 24-72h following IR injury,23 delivery vehicles that rely on passive 
macrophage-mediated release do not inhibit the excessive apoptosis that occurs in CMs 
during the initial 72h. Drug delivery vehicles that target CMs are virtually nonexistent, 
owing largely to the non-phagocytic nature of these cells. However, recent studies have 
implicated N-acetyl-D-glucosamine (GlcNAc) as a viable candidate for a drug delivery 
system targeted to CMs, demonstrating the ability of CMs to bind to and internalize 
GlcNAc-decorated liposomes.24, 25 The use of liposomes as a drug delivery vehicle, 
however, may lead to challenges: leakage of water-soluble drugs during preparation and 
storage is a known disadvantage; and the destabilization of liposomes in the presence of 
high-density lipoproteins in blood plasma limits its use.158 
Previously, we inhibited chronic cardiac dysfunction through the controlled 
release of the p38 inhibitor SB239063 from microparticles into the extracellular region of 
the post-infarcted heart.32 Despite this improvement in chronic function, there was no 
change seen in early function, indicating release was not fast enough or the inhibitor was 
not taken up by the appropriate cell type. In vitro, macrophages readily phagocytosed 
the particles whereas other cell types did not, most likely due to lack of targeting agents. 
In this study, we developed a drug delivery system for enhanced CM uptake by 
decorating degradable, biocompatible polymeric nanoparticles (polyketals) with GlcNAc 
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(cartoon depiction in Figure 3.1) and demonstrated its ability to be internalized by CMs. 
Using these GlcNAc particles, we were able to reduce infarct size and improve acute 





Figure 3.1. Overall scheme for proposed GlcNAc-mediated drug delivery system. A) 
Decoration of drug-loaded polymeric nanoparticle with GlcNAc should provide a mechanism 
whereby therapeutics may be delivered intracellularly to CMs. B) The particle will be composed of 
the acid-labile PCADK. Once internalized, the particle will degrade into the biocompatible 




3.2 Materials and methods 
3.2.1 Synthesis of GlcNAc-alkyl 
GlcNAc-alkyl (1) was synthesized by clicking an azide-modified GlcNAc (6) onto 
an alkyne-functionalized alkyl-hexaethylene glycol (7) (shown in Figure 3.2). The azide-
modified GlcNAc (6) was synthesized by functionalizing the anomeric carbon of GlcNAc 
(2) in three steps. Briefly, the hydroxyl groups of GlcNAc were protected with acetic 
anhydride in pyridine, generating (3). The anomeric acetyl of (3) was activated with lewis 
acid to form the oxazoline donor, and then coupled with azido-propanol, using TMSOTf 
as the catalyst to afford the desired derivative (6). The final product GlcNAc-alkyl (1) was 
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synthesized by clicking the GlcNAc (6) onto the alkyl-hexaethylene glycol (7) in presence 
of catalyst copper(I) bromide, followed by deacetylation. The identities of final and 
intermediate species were confirmed by 1H- and 13C-nuclear magnetic resonance (NMR) 
and mass spectrometry. Compound (1) 1H-NMR (400 MHz, CDCl3): δ (parts per million 
(ppm)) 7.57(s, 1H, triazole), 4.94 (t, 1H, J = 8.8 Hz), 4.56 (m, 2H), 4.48 (m, 1H), 4.36-
4.33 (m, 2H), 4.14-4.12 (m, 2H), 3.77-3.57 (m, 26H), 3.25 (m, 2H ), 3.30 (m, 2H), 2.07 
(m, 2H), 1.98 (s, 3H), 1.40 (m, 2H), 1.22-1.13 (m, 31H). 13C-NMR (100 MHz, CDCl3): δ 
(ppm) 173.8, 156.4, 145.1, 123.5, 101.2, 76.7, 75.7, 70.7, 70.5, 70.4, 70.3, 69.7, 65.2, 
64.5, 63.6, 61.6, 56.6, 53.4, 46.6, 41.0, 31.9, 30.1, 29.9, 29.7, 29.6, 29.5, 29.3, 29.2, 
26.7, 23.3, 22.7, 14.1. High resolution mass spectra (HRMS) fast atom bombardment 





Figure 3.2. Synthetic scheme of GlcNAc-alkyl. A facile and scalable eight-step process is 
followed to produce the tethering and targeting compound GlcNAc-alkyl. During nanoparticle 
production, the hydrophobic alkyl chain associates with the polymeric particle and the hydrophilic 





3.2.2 PCADK synthesis 
PCADK was synthesized as previously described.30 Briefly, 2,2-
dimethoxypropane was reacted with 1,4-cyclohexanedimethanol in an acetal exchange 
reaction in distilled benzene at 100°C with p-toluenesulphonic acid as the polymerization 
catalyst. 2,2-dimethoxypropane was supplied to the reaction in an equimolar ratio to 1,4-
cyclohexanedimethanol. To compensate for the loss of benzene and 2,2-
dimethoxypropane through distillation, additional amounts were added every two hours. 
At 8 hr, a small amount of triethylamine was added to the reaction vessel to stop the 
reaction. Adding this reaction mixture dropwise to cold hexanes (-20°C) precipitated out 
the polymer, which was then removed by vacuum filtration and dried prior to particle 
formation.  
3.2.3 Particle production 
Polyketal particles loaded with rhodamine B (Sigma-Aldrich) (PK-GlcNAc-
rhodamine) were prepared via a solvent displacement method. Briefly, a solution of 40 
mg PCADK and 0.2 mg Rhodamine B in 8 mL tetrahydrofuran was added dropwise into 
a vigorously stirred aqueous solution of 1% GlcNAc-alkyl. The resulting stirred 
suspension was vented for 6h to allow for evaporation of solvent. 
Polyketal particles loaded with 5-chloromethylfluorescein diacetate (CMFDA) 
(Invitrogen) (PK-GlcNAc-CMFDA), (9'-(4-(and 5)-chloromethyl-2-carboxyphenyl)-7'-
chloro-6'-oxo-1,2,2,4-tetramethyl-1,2-dihydropyrido[2',3'-6]xanthene (Invitrogen) (PK-
GlcNAc-CMRA), or SB239063 (Axxora) (PK-GlcNAC-SB) were generated using an 
emulsion-solvent evaporation technique. Fifty mg of PCADK and cargo (0.25 mg 
CMFDA, 100 µg CMRA, or 0.5 mg SB239063) were dissolved in 1 mL of 
dichloromethane. The polymer solution was then added to 7 mL of 5% polyvinyl alcohol 
(PVA) and 5 mg GlcNAc-alkyl (or 0.5 mg GlcNAc-alkyl for 1% decoration of PK-GlcNAc-
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CMFDA particles), homogenized at high speed for 60s, and sonicated for 30s to produce 
nanoparticles. The resulting emulsion was transferred to 30 mL of 0.5% PVA and stirred 
at approximately 100 rpm for 4h to allow for evaporation of solvent. All of the particle 
suspensions were then centrifuged and washed with deionized water three times to 
remove residual PVA and GlcNAc-alkyl, as well as non-encapsulated cargo. The 
suspension was then snap frozen in liquid nitrogen and lyophilized to produce a free 
flowing powder. 
3.2.4 Particle characterization 
Particles were sized by a Wyatt DynaPro Nanostar dynamic light scattering 
(DLS) instrument (Wyatt Technology) and imaged by a Zeiss Ultra 60 scanning electron 
microscope (SEM). Nanoparticle circumferences were traced using ImageJ software to 
confirm DLS-determined sizes. Zeta potentials of particles in phosphate buffered saline 
(PBS) buffer (pH 7.4) were measured by a Malvern Instruments Zetasizer.  
To determine cargo content, loaded and non-loaded particles were hydrolyzed 
overnight in 1 N HCl. Quadruplicates of 1 mg each of CMFDA-loaded nanoparticles (0%, 
1%, and 10% decorated PK-GlcNAc-CMFDA particles) were hydrolyzed in 100 mL HCl 
at 80°C for 3h. To activate CMFDA fluorescence, 200 mL Ba(OH)2 was added to each 
sample heated at 80°C for 3h. Following neutralization with 10x PBS, solutions were 
snap frozen in liquid N2 and lyophilized to concentrate CMFDA. All readings were 
performed in 100 mL PBS, and fluorescence determined via plate reader 
(excitation/emission (exc/emi) = 492/517 nm) (BioTek Synergy 2) and loading amount 
calculated from a standard curve generated using free CMFDA (r2=0.99). The 
absorbance of resultant solutions containing SB239063 was measured at 320 nm and 
loading efficiencies calculated from a standard curve generated using free SB239063 
(r2=0.99). 
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Degree of decoration was measured by first hydrolyzing 5 mg of PK-GlcNAc 
(with a theoretical decoration of 10% and 1%) and PK particles (in triplicate) in 1 N HCl, 
followed by neutralization with NaOH. The absorbance of the resulting solutions was 
measured at 278 nm in a plate reader and wt% decoration calculated from a standard 
curve generated from free GlcNAc-alkyl (r2=0.99). GlcNac-alkyl decoration was 
orthogonally confirmed by analyzing molecular species by electrospray ionization mass 
spectrometry. 
3.2.5 SB release characterization 
2 mg of PK-GlcNAc-SB and PK-GlcNAc particles in triplicate were suspended 1 
mL PBS (pH 7.4) and set on an inverting rotator (0.25 Hz) at 37°C. At specified 
timepoints, suspensions were spun at 13.3 rpm for 5 min to pellet particles and 100 µL 
supernatant removed for analysis. 100 µL fresh PBS was added to compensate and 
particles resuspended. The absorbance of the samples was measured at 320 nm and 
concentration calculated from a standard curve of free SB239063 (r2=0.99). At the end of 
the experiment, the particles were hydrolyzed to determine the amount of remaining 
SB239063, and a release curve was generated accounting for amount of SB239063 
released from and remaining in particles. 
3.2.6 CM isolation 
CMs were isolated from day-old Sprague Dawley rat pups as previously 
described 24, 31. Briefly, excised rat hearts were washed with Hank’s Balanced Salt 
Solution (HBSS) and minced, followed by extracellular matrix digestion in 1 mg/mL 
trypsin solution in a rotating shaker at 4°C for 6h. Following centrifugation, the 
supernatant was removed and pellet re-suspended in 0.8 mg/mL collagenase solution. 
The suspension was incubated at 37°C for 10 min and filtered through 70 mm syringe 
filter. To remove vascular smooth muscle cells and endothelial cells, the suspension was 
 39 
plated for 1h in fibronectin-coated T75 flasks. The non-adherent cells were removed and 
plated in fibronectin-coated 6- or 12-well plates in antibiotic-supplemented Dulbecco's 
Modified Eagle Medium (DMEM) media (10% fetal bovine serum (FBS)). Twelve hours 
before treatment, cells were quiesced in serum-free media. 
3.2.7 Imaging of rhodamine-loaded particles in cells 
A 0.5 mg/ml particle suspension of rhodamine-loaded, GlcNAc-decorated 
particles in serum-free DMEM media was added to quiesced CMs. After incubation at 
37°C for 12h, cells were washed three times with PBS and cells fixed in 4% 
paraformaldehyde (PFA). Following membrane permeabilization, immunostaining was 
performed with mouse anti-α-actinin (Sigma-Aldrich) and 4',6-diamidino-2-phenylindole 
(DAPI) to stain nuclei. Cells were imaged with a Zeiss 510 META confocal laser 
scanning microscope. 
3.2.8 Determining uptake of CMFDA-loaded particles in cells 
A 0.5 mg/ml suspension of CMFDA-loaded or non-loaded particles with varied 
levels of GlcNAc decoration was prepared in serum-free DMEM media and added to 
quiesced CMs. Following incubation at 37°C for 12h, fluorescence of cells was 
measured by plate reader (exc/emi = 492/517 nm). 
3.2.9 Treatment of CMs with PK-GlcNAc-SB 
Quiesced cells were incubated with 0.5 mg/mL of PK-GlcNAc-SB or PK-GlcNAc 
particles in serum-free DMEM at 37°C for 18h, followed by stimulation with TNF-α (10 
mg/mL) 20 min. Cells were harvested in lysis buffer with protease and phosphatase 
inhibitors. Western analysis for p38 activation was performed on 35 µg of protein lysate. 
Following SDS-PAGE separation, proteins were transferred to a nitrocellulose 
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membrane and probed with antibodies against phosphorylated or total p38 (Cell 
Signaling).  
3.2.10 Animal studies  
Randomized and blinded studies were conducted using adult male Sprague-
Dawley rats (obtained from Charles River) weighing 250 g. Rats were subjected to IR 
injury as described previously.159 Briefly, under isoflurane anesthesia (1-3%), the left 
anterior descending coronary artery was occluded for 30 minutes using an 8-0 prolene 
suture. Following occlusion, reperfusion was initiated by removal of the suture and 
animals were divided into treatment groups. Particle suspension treatments were given 
in 100 mL of sterile saline into the perimeter of cyanotic ischemic zone (3 locations) 
through a 30-gauge needle immediately after reperfusion. The survival rate of animals 
during surgery was 80%, and 100% during recovery. All animal studies were approved 
by Emory University Institutional Animal Care and Use Committee. 
To examine in vivo uptake of particles, rats were divided into three treatment 
groups: saline alone, PK-CMRA, and PK-GlcNAc-CMRA (n=3 for each group). Three 
days following IR and treatment, rats were sacrificed and hearts excised. After 
preservation in Optimal Cutting Temperature (OCT) compound (Tissue-Tek), hearts 
were sectioned into 7 µm thick slices and immunostaining performed with anti-α-actinin 
(Sigma-Aldrich) and DAPI to stain nuclei. Tissues were imaged with a Zeiss 510 META 
confocal laser scanning microscope (CMRA exc/emi = 548/576 nm). 
 In vivo reduction of apoptotic events was explored by dividing the rats into three 
treatment groups: saline alone, empty PK-GlcNAc, and PK-GlcNAc-SB (n=3 for each 
group). One day following IR and treatment, rats were sacrificed and hearts excised. 
After cryopreservation in OCT compound, hearts were sectioned and subject to 
immunostaining for α-actinin and DAPI. Tissues were subject to Terminal 
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deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) in situ apoptosis detection, 
tetramethylrhodamine (TMR) red (Roche) to stain for apoptotic nuclei and imaged with a 
Zeiss Axioskop microscope. Using Image-Pro Plus software (MediaCybernetics), 
apoptotic and total nuclei were tallied and extent of apoptosis calculated for each 
treatment group. 
For structural and functional experiments, rats were split into three groups: saline 
alone, PK-GlcNAc, and PK-GlcNAc-SB (n>7 for each group, N=29 total). Additionally, 
some animals received sham surgery. Echocardiography was performed three days 
following surgery. The animals were sacrificed and immediately perfused for infarct size 
measurements. 
3.2.11 Echocardiography 
Rats were anesthetized with inhaled isoflurane (1-3%; Piramal) and subjected to 
echocardiography 3 days after IR surgery. Short axis values of left ventricular end 
systolic and end diastolic dimension were obtained using a Vevo® 770 echocardiography 
workstation with a high frequency transducer. An average of 3 consecutive cardiac 
cycles was used for each measurement and was made 3 times in an investigator-blinded 
manner. 
3.2.12 Infarct size 
Three days following IR, animals were sacrificed and isolated hearts perfused at 
37°C retrograde through the aorta with Krebs-Hepes buffer. The coronary artery was 
then re-occluded with the suture that was left in place at the time of reperfusion and the 
heart was perfused with filtered Evan’s blue dye to define the LV area at risk. The LV 
was sliced into cross-sections followed by 2 min soaking in 1% 2,3,5-triphenyltetrazolium 
chloride (TTC) solution at 37°C to stain viable myocardium, followed by fixing in 4% PFA. 
Each section was photographed for analysis. Non-infarcted tissue (region outside the 
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ligated area) was identified by deep blue staining, ischemic but viable myocardium was 
identified by deep red staining (at-risk area), and non-viable LV tissue was identified by 
white coloration. ImageJ software was used to trace the three areas in all sections. The 
areas of the three regions from all slices were summed for each heart and data were 
expressed as infarct size/area-at-risk (IS/AAR). 
3.2.13 Statistics 
All statistics were performed using GraphPad Prism software.  
3.3 Results 
3.3.1 CM internalization of PK-GlcNAc-rhodamine nanoparticles 
Cultured CMs harvested from day-old Sprague-Dawley rat pups were incubated 
with rhodamine-loaded, GlcNAc-decorated particles prepared by a solvent displacement 
method. Particles were imaged by SEM and analyzed by ImageJ software and had an 
average diameter of 320±156 nm (mean+SD; Figure 3.3 a). Cells were incubated with 
particles for 6h and analyzed by confocal microscopy to visualize particle uptake. To 
determine cell morphology, sections were counterstained with the cardiac-specific 
marker α-actinin (green) and images were merged to determine overlay. As 
demonstrated in the orthogonal images, rhodamine-loaded GlcNAc particles (red) were 






Figure 3.3. Incubation of CMs with PK-GlcNAc-rhodamine particles for internalization 
verification. A) Rhodamine-loaded particles (diameter = 320 ± 156 nm) were decorated with 
GlcNac-alkyl and imaged by SEM. B) Cultured CMs were treated with PK-GlcNAc-rhodamine 
particles for 12 h before fixation in PFA and immunostaining for CM-specific α-actinin (green) and 
DAPI for nuclei (blue). Confocal microscopy afforded orthogonal views of the cell, by which 




3.3.2 CM internalization of PK-GlcNAc-CMFDA nanoparticles in vitro 
To further demonstrate particle internalization, GlcNAc-decorated (0%, 0.6%, 9% 
as determined experimentally) CMFDA-loaded nanoparticles were prepared via a single 
emulsion method. Following hydrolysis of particle samples and fluorescence activation, 
average CMFDA encapsulations were determined by plate reader to be 2.9, 5.1, and 4.3 
nmol CMFDA/mg particle for 0%, 0.6%, and 9% sugar decoration, respectively (Figure 
3.4 a). 
The fluorescence of cultured CMs treated with CMFDA-loaded nanoparticles for 
12h was determined by plate reader and normalized to the 0% GlcNAc particles and the 
respective particle CMFDA content. Cells treated with 0.6% GlcNAc decorated particles 
exhibited a 1.4±0.1-fold increase in fluorescence, whereas treatment with 9% GlcNAc 
particles resulted in a significant 2.8±0.1-fold increase in fluorescence over cells treated 
with CMFDA-loaded, non-decorated particles (mean±SEM; n=4; *p<0.01, ***p<0.001. 






Figure 3.4. Measurement of particle internalization by CMFDA fluorescence demonstrating 
increased uptake. PK-GlcNAc-CMFDA nanoparticles were decorated with 0%, 0.6%, or 9% 
GlcNAc-alkyl by weight and loaded with the cell tracker dye, 5-CMFDA. A) Particles are closely 
load-matched for CMFDA content: 0%, 0.6%, and 9% decorated particles contained 2.9 ± 0.3, 5.1 
± 1.5, and 4.3 ± 0.2 nmol CMFDA/mg particle, respectively. Data are expressed as mean±SEM 
from three experiments. B) After incubation of CMs with particles, fluorescence of cell culture was 
obtained by a plate reader and normalized to 0% GlcNAc-alkyl decoration and respective particle 
CMFDA content. The positive correlation between fluorescence and degree of decoration 
indicates a dose response and confirms cell uptake of GlcNAc-decorated particles. Data are 
expressed as mean ± SEM from four separate experiments (*p < 0.05, ***p < 0.001; ANOVA 




3.3.3 In vitro inhibition of p38 activation 
PK-GlcNAc-SB and PK-GlcNAc particles were prepared by a single emulsion 
method and had a mean diameter of 370 nm by SEM image analysis and DLS (Figure 
3.5 a&b). A cumulative release curve of SB239063 from PK-GlcNAc-SB particles was 
generated, with 24% released by day 5 in a 2 mg/mL suspension (Figure 3.5 c).  
To evaluate in vitro particle internalization, CMs were pretreated with serum free 
media alone or particles for 18h and stimulated with TNF-α (10 mg/mL) for 20 minutes. 
Proteins were run on SDS-PAGE gel and membranes were stained for both 
phosphorylated and total p38 levels. Band densities were calculated by Carestream 
Health Imaging software. The amount of p38 phosphorylation (p-p38) was normalized to 
total p38 for each treatment (Figure 3.5 d). TNF-α stimulation significantly increased p-
p38 over basal levels in PK-GlcNAc pretreated CMs (0.7±0.1 to 1.8±0.2), but not in the 
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PK-GlcNAc-SB pretreated cells. Additionally, the amount of TNF-a-stimulated p-p38 was 
significantly decreased in PK-GlcNAc-SB cells compared with PK-GlcNAc pretreatment 





Figure 3.5. Treatment of CMs in vitro with p38 inhibitor-loaded nanoparticles reduces TNF-
α-stimulated p38 activation. PK-GlcNAc and PK-GlcNAc-SB particles were imaged via a SEM 
(diameter = 407 ± 125 nm or diameter = 342 ± 165 nm, respectively) and b) analyzed by DLS 
(diameter = 465 ± 173 nm or diameter = 395 ± 145 nm, respectively). Data are mean ± SD. C) 
PK-GlcNAc-SB particles release cargo through diffusion at pH 7.4. D) PK-GlcNAc did not prevent 
p38 phosphorylation, as demonstrated by a 2.4-fold increase of p-p38 due to TNF-α treatment. 
However, PK-GlcNAc-SB treatment significantly inhibited p38 activation compared with empty 
particles. Data are mean ± SEM and are expressed as a ratio of phosphorylated to total p38 (n = 





3.3.4 In vivo uptake of PK-GlcNAc-CMRA particles and apoptotic inhibition by PK-
GlcNAc-SB particles 
To examine the ability of the GlcNac-decorated particles to be internalized in vivo, 
a blinded and randomized model of IR injury was used. Following 30 minutes of 
ischemia, the LV was reperfused and rats received injections of saline, PK-CMRA 
(average diameter=443 nm), or PK-GlcNAc-CMRA (average diameter=453 nm) particles 
in a randomized and blinded manner (n=3 for each group). Three days following IR, 
animals were sacrificed and hearts excised, snap frozen in OCT compound, and 
sectioned. Using immunohistochemistry, CMs were identifiable by α-sarcomeric actinin 
staining (green). CMRA-positive cells were identified by red fluorescence, and 
representative co-localization images are shown in Figure 3.6 a. Qualitative data from 
the images suggest efficient in vivo uptake of PK-GlcNAc-CMRA with little staining in 






Figure 3.6. GlcNAc decoration enhances particle uptake in vivo following IR and reduces 
apoptotic events. A) Rats that received myocardial injection of (9’-(4-(and 5)-chloromethyl-2-
carboxyphenyl)-7’-chloro-6’-oxo-1,2,2,4-tetramethyl-1,2-dihydropyrido[2’,3’-6]xanthene) (CMRA)-
loaded GlcNAc-decorated particles (PK-GlcNAc-CMRA) immediately following IR exhibited a 
greater CMRA fluorescence 3 days post-IR than animals that had received PK-CMRA particles, 
indicating enhanced in vivo uptake due to GlcNAc decoration. B), C) Immediately following IR, 
particles were injected intramyocardially and hearts removed 1 day post-IR. TUNEL staining 
indicated apoptotic nuclei (b) (apoptotic nuclei [purple] indicated by arrow, non-apoptotic nuclei 
[blue] indicated by triangle), and comparison against total CM nuclei indicated that animals that 
received PK-GlcNAc-SB particle injections achieved 3.6-fold fewer apoptotic events in the injured 
myocardium compared to IR and 2.7-fold fewer than the PK-GlcNAc group (c) (n = 3 for each 





After establishing that GlcNAc-decorated particles are internalized by CMs in vivo, 
we sought to evaluate the anti-apoptotic effect of PK-GlcNAc-SB particles in vivo in a 
randomized and blinded manner. Using the IR rat model, we injected saline, PK-GlcNac, 
and PK-GlcNAc-SB particles (n=3 for each group) into the border zones of the LV as 
described in the methods. Twenty-four hours following IR, the rats were sacrificed, and 
TUNEL staining was performed for identification of the apoptotic nuclei (purple color; 
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Figure 3.6 b) of a-sarcomeric actinin-positive cells (green). The number of apoptotic CMs 
for each treatment group was determined and expressed as a percent of total CMs 
counted. We found that delivery of PK-GlcNAc-SB particles to the heart significantly 
reduced the percentage of apoptotic myocytes in the infarcted area as identified by 
TUNEL staining (Figure 3.6 b). In saline-only and PK-GlcNAc treated rats, 83%±14% 
and 64%±4% of CMs counted were TUNEL-positive (Figure 3.6 c). However, a 
significantly lower number of apoptotic CMs were counted in hearts treated with PK-
GlcNAc-SB particles (23%±6%) (*p<0.05 and **p<0.01; ANOVA followed by Newman-
Keuls post-test). Taken together, these data suggest that GlcNAc decoration of particles 
enhanced CM uptake in vivo, and delivered anti-apoptotic signals following IR. 
3.3.5 In vivo cardiac function 
We next sought to determine the ability of the SB-loaded particles to rescue rats 
from acute cardiac dysfunction. Following 30 minutes of ischemia, the LV was 
reperfused and rats received injections of saline, PK-GlcNAc, or PK-GlcNAc-SB particles 
in a randomized and blinded manner. Three days following IR, rats were subjected to 
small animal echocardiography (n=4 for sham, n>7), prior to determination of infarct size 
using TTC staining. Saline treated rats had an infarct size/area-at-risk (IS/AAR) of 
43.7%±5.6% (Figure 3.7 a). While no significant difference was seen in rats that 
received PK-GlcNAc particle injection post-IR (IS/AAR = 49.4%±3.1%), rats that 
received PK-GlcNAc-SB particles had a significant reduction in IS/AAR (28.4%±3.2%; 






Figure 3.7. Infarct size reduction and functional improvements seen in PK-GlcNAc-SB 
treatment following ischemia–reperfusion injury. Immediately following IR, particles were 
injected directly into the injured myocardium. Three days following surgery, echocardiography 
was performed and heart cross sections analyzed for infarct size. A) The ratio of infarct size to 
area at risk was calculated for the treatment groups. PK-GlcNAc treatment had no significant 
effect, but PK-GlcNAc-SB treatment significantly decreased infarct size compared to both 
treatment groups (mean ± SEM, n = 5; *p < 0.05, **p < 0.01; ANOVA followed by Newman–Keuls 
multiple comparison post test). B) Fractional shortening calculated from echocardiographic 
measurements demonstrated a significant decrease in function in IR animals compared to sham. 
There was no significant improvement seen with PK-GlcNAc, though PK-GlcNAc-SB treatment 
improved function compared with other IR groups (n = 4 for sham n > 7 for IR groups). Data are 




To determine functional changes, left ventricular diameters were measured at 
peak systole and diastole to determine fractional area of shortening (n=5). Sham-
operated rats had a fractional shortening (FS) of 50.5%±0.9% that was significantly 
lower in IR animals (39.6%±0.7%; p<0.05; ANOVA) (Figure 3.7 b). While no significant 
increase was seen in PK-GlcNAc treated rats (38.6%±1.7%), treatment with PK-GlcNAc-
SB significantly improved FS (44.4%±1.2%; p<0.05 vs. IR, p<0.05 vs. PK-GlcNAc; 
ANOVA). Taken together, these data demonstrate a positive effect of PK-GlcNAc-SB on 
cardiac function following IR. 
3.4 Discussion 
Apoptosis of CMs following IR is suggested to be the dominant cause of chronic 
heart failure,6, 148 but despite the existence of molecules with the potential to inhibit 
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apoptotic pathways, development of vehicles for intracellular drug delivery into CMs 
remains a large challenge for post-MI healing. Systems exist for sustained extracellular 
release of therapeutic molecules or that act through phagocytic cells, such as 
macrophages. However, potential therapeutics that act intracellularly are precluded from 
existing systems due to their inability to transmigrate cell membranes. Previous studies 
discovered that CMs bind to and internalize GlcNAc, providing a compelling targeting 
agent in CM-targeting drug delivery systems.24 The researchers delivered pravastatin (a 
3-hydroxy-3-methylglutaryl-CoA reductase inhibitor)-loaded GlcNAc-decorated 
liposomes to CMs and following stimulation with interleukin-1β, showed enhanced nitric 
oxide production and inducible nitric oxide synthase expression. However, the studies 
were limited to in vitro experiments and relied on liposomal vehicles, which are known to 
be unstable and leak water-soluble contents.158 In our approach, we decorated acid-
sensitive nanoparticles with GlcNAc and validated our delivery system both in vitro and 
in vivo. Our preliminary findings implicate GlcNAc-decorated nanoparticles as a novel 
method of delivering therapeutic molecules to CMs to heal the post-infarct heart. 
In our studies, we synthesized a targeting molecule consisting of GlcNAc 
tethered to an alkyl chain via a PEG linker. This was completed in a facile 8-step 
process with inexpensive materials. The reactions were conducted at the gram scale, 
but are scalable to kilogram quantities, allowing for larger production applications. 
Through hydrophobic interactions, the hydrophobic tail associated with the polymeric 
particle, allowing for the more hydrophilic sugar head group to partition into the aqueous 
phase to interact with CMs. In fact, this proposed particle-GlcNAc-alkyl interaction 
proved effective in decorating particles: in initial formulations of 10% and 1% by weight 
GlcNAc-alkyl to PCADK, the actual degree of decoration was 9 wt% and 0.6 wt%, 
respectively. This decoration of hydrophobic polymeric particles with hydrophilic GlcNAc 
increased the zeta potential from -8.97 mV (0% decoration) to -3.39 mV (9% decoration). 
 51 
We have used this strategy in prior studies to bind large proteins to the outside of 
microparticles. Additionally, this strategy is not all that uncommon and is used to surface 
modify hydrophobic polymers with hydrophilic molecules.31, 160 The polymer was 
composed of the polyketal PCADK that degrades in acidic environments, such as in the 
developing endosome. The byproducts are biocompatible (acetone is on the generally 
regarded as safe (GRAS) list and 1,4-cyclohexanedimethanol is Food & Drug 
Administration (FDA) approved as an indirect food additive and has an excellent animal 
toxicity profile30) and PCADK particles have been shown to neither incite the 
inflammatory response nor induce cell death.32 We are able to routinely produce 
nanoparticles ranging in size from 200 to 800 nm, which is small enough to allow for cell 
internalization and large enough to avoid being flushed from the injured myocardium.  
To initially demonstrate enhanced cellular uptake due to GlcNAc-decoration, 
particles were loaded with rhodamine B and incubated with CMs. Confocal images taken 
12 hr later presented evidence of particle internalization wherein red nanoparticles were 
positioned within cells, visible within orthogonal frames. However, to more quantifiably 
determine internalization, we produced size- and load-matched particles with 0%, 1%, or 
10% GlcNAc-alkyl decoration that contained the cell tracker dye CMFDA. The dye is 
non-fluorescent until activated by intracellular esterases and becomes cell impermeant 
by reaction with glutathione, thus fluorescence should only been seen when the CMFDA 
is released from the particles into the cell. To account for any CMFDA release from non-
internalized particles, we normalized fluorescent readings to non-GlcNAc decorated 
CMFDA-loaded particle treatment. This approach allowed us to attribute fluorescence 
increase only with internalized particles. By comparing against the 0% decoration control, 
we saw a significant increase in fluorescence at 10% GlcNAc decoration, which 
confirmed that increasing GlcNAc decoration enhanced cellular uptake. While particle 
hydrolysis is possible outside the cell, which would allow release of the cell permeable 
 52 
CMFDA in the media, our published studies would argue against that. The hydrolysis 
half-life of PCADK polymer at pH 7.4 was four years in serum-free media,30 and thus it 
was unlikely that significant amounts of the hydrophobic CMFDA were released into the 
media. Furthermore, we examined release of CMFDA over 12 hr in cell free conditions 
and found no differences between the different particle preparations. The positive trend 
between degree of GlcNAc decoration and fluorescence increase implicates varying 
GlcNAc decoration to tune internalization kinetics, though more data points are needed. 
Moreover, it was suggested in prior studies that oligosaccharide decoration may also 
enhance uptake, setting the stage for a multi-sugar decorated particle to alter cell 
specificity.25 We did not explore the mechanism for GlcNAc internalization, but findings 
from a recent study indicate that the intermediate filaments vimentin and desmin 
possess lectin-like domains on the cell surface that bind to and internalize GlcNAc.25 
Although vimentin and desmin are not unique to CMs, they are enriched in muscle 
cells161 and gene knockouts demonstrate negative cardiac phenotypes.162 
The MAPK p38 is known to be a key regulator of apoptotic pathways and is 
triggered by IR.163-165 While our prior studies confirmed that PCADK was able to deliver 
therapeutics to macrophages, significant activation of p38 in CMs leads to apoptosis, 
activation of inflammatory genes, and stimulation of pro-fibrotic factors. Previously, we 
incubated CMs with SB239063-loaded non-decorated PCADK particles and analyzed 
TNF-stimulated p38 activation at several time points. We found no significant decrease 
in activated p38 when comparing inhibitor loaded and empty PCADK particles up to 6 hr, 
indicating that CMs internalized little non-sugar decorated particle, correlating with our 
current study using CMFDA. As our CMFDA data demonstrated significant uptake at 18 
hr, we used this time point to determine efficacy of our inhibitor-loaded GlcNAc particles. 
After 18 hr of incubation with PK-GlcNAc or PK-GlcNAc-SB, we examined kinase activity 
by measuring TNF-a-stimulated p38 phosphorylation. We found that while PK-GlcNAc 
 53 
(empty particle) treatment did not prevent p38 activation by TNF-a, treatment with PK-
GlcNAc-SB did prevent this activation, suggesting internalization of particles and release 
of the inhibitor. Additionally, p38 activation was verified through a no particle control 
treatment, with a 1.8-fold increase in p-p38 due to TNF-a treatment. The delivery of 
SB239063 to cells via non-internalization means (i.e. extracellular release) in the acute 
phase is relatively low; our release curve indicates that only up to 13% of SB239063 
may be released outside cells at pH 7.4 within three days. Though the current study only 
examined a small molecule p38 inhibitor, we have demonstrated the ability of PCADK 
particles to encapsulate a broad range of compounds from siRNA to proteins, and future 
work will determine whether these cell impermeant factors can also be delivered 
intracellularly to CMs. 
To evaluate the applicability of our GlcNAc-decorated nanoparticle as a drug 
delivery system to CMs in vivo, we first examined the enhanced uptake of GlcNAc-
decorated particles and then the anti-apoptotic effect of PK-GlcNAc-SB particles before 
assessing functional responses. We injected a saline particle suspension into the 
myocardium immediately following IR and evaluated cardiac function and structure in the 
acute temporal window. Although injection of small molecule therapeutics would be 
possible in a clinical setting, small molecules are cleared quickly from the well-perfused 
heart. We examined direct particle injection to the myocardium as intramyocardial 
injections in humans has been performed for cell therapy applications and is considered 
safe.166-168 Although signaling cascades persist for weeks following MI and therapeutic 
treatments would benefit from sustained delivery, acute therapies are also needed. Our 
published data demonstrated that sustained inhibition of p38 by particles in vivo had a 
chronic—but little acute—benefit. Therefore we hypothesized that delivery of particles 
with enhanced CM uptake would improve acute myocyte survival. We qualitatively found 
that more CMs internalized CMRA-loaded particles due to GlcNAc decoration, validating 
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in vivo applicability of this delivery system. Furthermore, the anti-apoptotic effect of PK-
GlcNAc-SB particles was successfully demonstrated in vivo following IR through the use 
of TUNEL staining: a 3.6-fold decrease in apoptotic CMs was observed due to PK-
GlcNAc-SB treatment from the saline-only treatment. While the levels of TUNEL-positive 
cells in our studies seem rather high, it is important to note that much of our 
measurement comes from the border zones as that is where therapy was introduced. A 
more thorough study of apoptosis is underway. 
In the structural response of rat model, no significant reduction in infarct size was 
seen between IR and PK-GlcNAc treatments, indicating no benefit of the empty sugar 
particle. However, delivering PK-GlcNAc-SB particles to the injured myocardium 
significantly decreased infarct by 35% from IR animals, indicating improved myocyte 
survival. While CM survival was not directly measured via cellular markers, infarct size is 
a well-known indicator of CM damage. This protective effect of PK-GlcNAc-SB was not 
only seen on infarct size, but cardiac function as well. Our data demonstrated significant 
decreases in FS in IR and PK-GlcNAc groups as compared with sham-operated animals. 
However, PK-GlcNAc-SB particle treatment restored nearly 50% of lost function over IR 
levels. While this was not restored to sham levels, the improvement was significant and 
indicates a functional benefit of GlcNAc-decorated particles loaded with a p38 inhibitor. 
We did not directly compare with non-decorated, inhibitor-loaded particles in our 
current study because it was unnecessary to duplicate negative data we previously 
produced utilizing animal studies.32 In that study, rats that received the p38-loaded 
inhibitor in PCADK particles had FS values similar to empty GlcNAc particle- and saline-
treated IR rats (below 40%). Statistical comparison indicated no significant differences 
between those treatments, and PK-GlcNAc-SB was significantly improved over PCADK-
SB particles, despite it being a separate study. It is important to note that we did not 
examine long-term function in this study, and the effect of sugar decoration on particle 
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efficacy in the chronic phase is unknown. As our prior barrier was lack of efficacy during 
the acute phase, we only examined this time point. One would hypothesize that 
increasing CM uptake would lead to a rapid depletion of drug-loaded nanoparticles 
available in the myocardium. While some studies suggest that inhibiting early apoptosis 
is critical for long-term function,169, 170 our prior studies with encapsulated SOD suggest 
that inhibition of apoptosis alone may not be sufficient for long-term improvements.159 
Thus, the optimal therapy may involve a mixture of decorated and non-decorated 
nanoparticles to target both phases of post-MI cardiac dysfunction. In future studies, we 
will determine the long-term benefit of PK-GlcNAc-SB treatment and determine whether 
this early rescue of function leads to long-term improvements; or if combination with 
PCADK-SB particles that chronically inhibited p38 in macrophages gives a synergistic 
effect. Finally, despite the fact that GlcNAc glycosylation of proteins improves function of 
CMs and may play a role in the response following infarction,171 we saw no beneficial 
effect of empty PK-GlcNAc particles. The studies demonstrating a critical role for this 
sugar did so by altering the activity or expression of the enzyme O-GlcNAc transferase 
(OGT). Thus the potential exists for the empty PK-GlcNAc particles to possess 
bioactivity in the setting of altered OGT activity. While not explored in our studies, 
encapsulation of OGT within PK-GlcNAc nanoparticles could have therapeutic potential. 
In summary, our work172 demonstrates that GlcNAc-decorated nanoparticles can 
be effective vehicles for intracellular delivery of therapeutic molecules to CMs. As 
verified by confocal microscopy and fluorescent plate readouts, CMs effectively 
internalized dye-loaded GlcNAc-decorated particles. Additionally, we demonstrated in 
vitro therapeutic delivery of the p38 inhibitor, SB239063, to CMs and validated GlcNAc-
decorated nanoparticles as in vivo delivery vehicles by decreasing infarct size and 
restoring cardiac function. The lack of uptake of some molecules by non-phagocytic CMs, 
toxic doses required of others, and sustained temporal availability preclude systemic 
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delivery of most therapeutics as a method of treatment following MI. With the large 
scalability and non-toxic nature of the nanoparticles, as well as the ability to encapsulate 
a variety of compounds, the clinical potential is quite compelling. The proposed delivery 
system described in this study demonstrates a potential means to enrich intracellular 
therapeutics within CMs, providing a novel vehicle for treatment for acute myocardial 




DENDRIMERIC BOWTIES FEATURING HEMISPHERIC-SELECTIVE 





The development of miR-based therapies holds exciting promise for improving 
the status quo of medicine.13 Delivery of traditional pharmaceuticals has faced significant 
limitations: protein-based therapeutics are generally restricted to extracellular receptors; 
and small-molecule drugs modulate only certain functions of their targeted protein and 
are limited in specificity. In contrast, by exploiting endogenous post-transcriptional 
mechanism by delivering synthetic miR mimics, genetic pathways can be regulated 
selectively.14 The range of miR-based pharmaceuticals is wide, with potential 
applications ranging from cancer to diabetes and heart failure. 
However, challenges exist in the development of such therapies such as 
protecting the miR molecules from ribonucleases (RNases),14 and difficulty inducing 
cellular uptake by the target cell population. RNases that are present in bodily fluids 
readily degrade miR, requiring protective measures, such as encapsulation of the miR26 
or the use of chemically modified RNA.27 The highly charged backbone and size of 
nucleic acids precludes passive cell penetration,14, 173 necessitating incorporation of a 
mechanism for cellular uptake in most cell types. Additionally, specificity in targeting 
certain cell types is generally desired in order to reduce miR uptake in unintended cells. 
Dendrimers, a class of radially symmetric, regularly branched polymers, have 
been extensively studied as delivery agents for a variety of drugs.174-176 One well studied 
dendrimer is PAMAM, which generally consists of an ethylenediamine core that is 
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reacted alternatively with methyl acrylate and ethylenediamine to form a size-tuned 
dendrimer that features amino termini.177 Traditional strategies have largely consisted of 
physical entrapment of drugs within the relatively hydrophobic dendrimer core, with 
conjugated targeting moieties distributed among the dendrimer terminal groups. As such, 
dendrimers are attractive multi-functional nanomaterials despite some side effects, such 
as cytotoxicity.36 Recent studies have extended dendrimer applications to siRNA- and 
miR-based therapeutics.37, 38, 40, 65, 176, 178, 179 The suitability of a dendrimer-based RNAi 
therapeutic lies in part with the amino groups present at the termini and within the 
dendrimer that afford electrostatic interactions with—and thereby encapsulation and 
protection of—anionic miR mimics.37 The interior amines can also provide “proton 
sponge” mechanisms for the endosomal escape of the trapped nucleic acids.179 Another 
compelling reason for dendrimer-based therapeutics is that the terminal amines can be 
readily conjugated with biomolecular ligands, which “decorate” the dendrimer with 
signals to potentially enhance cell targeting and uptake. Studies have indicated that 
varying the number of ligands on the vehicle surface elicits different binding and 
internalization kinetics, and dendrimeric materials can handily exert these “multivalent 
effects” by presenting an increased number, density, and arrangement of ligands.38-40, 180-
182 
However, previous studies in dendrimer delivery systems where ligands were 
conjugated to surface groups may have had a significant design shortcoming: greater 
ligand density may result in enhanced delivery, but as PAMAM dendrimers present a 
defined number of terminal amines, an increase in the number of terminal amines 
conjugated to ligands necessitates a decrease in the number and density of PAMAM 
terminal amines available for RNA binding. These competing uses of terminal groups 
may create an impasse in dendrimer vehicle design if the need for decorated termini 
allocates insufficient numbers of terminal groups for RNA binding, or vice versa. Thus, 
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the need exists for a new dendrimeric structure with a higher degree of spatial control 
over the surface functional regions for effective delivery of RNAi therapeutics. 
We present here the design and application of a novel multi-functional 
dendrimeric vehicle with two discrete regions: one that retains a high density of cations 
for RNA binding with the other region simultaneously presenting locally concentrated 
ligands that enhance cellular uptake. In this study, we prepared our “bowtie” dendrimer 
by coupling the cores of functionally unique reduced cystamine core PAMAM dendrimers. 
To promote binding of miR mimics, one side of the resulting dendrimeric bowtie 
consisted of one half of a generation 4 PAMAM (g4P) dendrimer, and the other side of 
the bowtie was one half of a generation 2 PAMAM dendrimer (g2P). The g2P presented 
either poly(arginine)9 (polyR)—a cell-penetrating peptide—or the peptide RGD, a 
component of the integrin-binding matrix that facilitates the cellular uptake of RGD-
bound particles. 
To demonstrate the suitability of our dendrimeric bowtie as a transfection vehicle, 
we loaded the bowties with miR-126 mimic—an important modulator of vascular integrity, 
endothelial cell proliferation, and neovascularization—and incubated the resulting 
complexes with HUVECs. Treatment with our bowties significantly enhanced cell 
proliferation and tube formation of HUVECs, and knocked down SPRED1 mRNA levels, 
a target of miR-126. 
4.2 Materials and Methods 
4.2.1 Materials 
Water was distilled and deionized at 18 MΩ resistance (Gelante Pure Water, 
Shijiazhuang, China). Peptides composed of sequences cysteine-glycine-glycine-
arginine-glycine-aspartic acid-serine (CGGRGD) and cysteine-(arginine)9 (polyR) were 
obtained from GL Biochem (Shanghai, China). GeneFinder nucleic acid dye was 
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purchased from Bio-V (Xiamen, China). 1,4-bis(maleimido)butane (BMB) coupler was 
purchased from Thermo Scientific. A HUVEC line was obtained from ScienCell, and 
daughter cells from passages under passage seven were used in in vitro experiments. 
Cells were cultured in endothelial cell medium (ECM, Cat. No. 1001, ScienCell) 
supplemented with 5% FBS (Cat. No. 0025, ScienCell), endothelial cell growth 
supplement (Cat. No. 1052, ScienCell), and penicillin/streptomycin (Cat. No. 0503, 
ScienCell). Opti-MEM reduced serum medium and Dulbecco’s phosphate buffered 
saline (DPBS) were purchased from Invitrogen. Double-stranded miR-126, non-
mammalian mRNA targeting negative control miR #22 (C. elegans miR cel-miR-239b-
59), and cy3-labeled control miR #22 mimics were synthesized by RiboBio (Guangzhou, 
China). The sequences for miR-126 mimic were 5’-UCG UAC CGU GAG UAA UAA 
UGC G dTdT-3’ (sense) and 3’-dTdT AGC ATG GCA CTC ATT ACG CAA-5’ (antisense). 
The sequences for control miR #22 were 5’-UUU GUA CUA CAC AAA AGU ACU G 
dTdT-3’ (sense) and 3’-dTdT AAA CAT GAT GTG TTT TCA TGA C-5’ (antisense). 
4.2.2 Synthesis 
Generation 4 and hydrazide-terminated generation 2 cystamine core PAMAM 
dendrimers (g4P and g2P, respectively) were prepared as previously described.180 
Peptide decoration of g2P was accomplished via the bifunctional coupler, succinimidyl-
([N-maleimido propionamido]-diethylene glycol) ester (SM(PEG)2, Thermo Scientific), 
which featured amine- and thiol-reactive termini (Figure 4.1 A). In DPBS, 0.93 mM g2P 
dendrimer and 30 mM SM(PEG)2 were reacted for 1 hour at room temperature. 
Following extensive washing in DPBS by centrifugal filtration (molecular weight cut off 
(MWCO) 3000, Millipore) to remove unreacted SM(PEG)2, RGD or polyR peptides (18 
mM final) were dissolved into reaction mixtures at a 1.2-fold excess to terminal groups. 
The reaction proceeded overnight at room temperature, followed by centrifugal filtration. 
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The modification levels of polyR or RGD on g2P was evaluated by analysis of 1H-NMR 





Figure 4.1. Synthesis and coupling of bowtie dendrimer. (A) Synthetic scheme for 
modification of g2P with RGD or polyR. (B) Cartoon of a synthetic scheme illustrating the coupling 




To generate dendrimeric bowtie conjugates (Figure 4.1 B), the reducing agent 
tris(2-carboxyethyl) phosphine (TCEP, 15 mM) was added to a solution of cystamine-
core g4P (0.15 mM) in DPBS to reduce the disulfide bond within the core of the 
dendrimer. The reaction solution contained 10 mM ethylenediaminetetraacetic acid 
(EDTA) to prevent disulfide re-formation. A 10-fold molar excess BMB dissolved in 
dimethyl sulfoxide (DMSO) was then added to react with the newly generated thiols of 
the resulting dendron. The reaction was carried out for 2 hours at room temperature. The 
resulting g4P-BMB intermediate conjugate was washed by extensive centrifuge filtration 
(MWCO 3000, Millipore) to remove excess BMB. In a parallel reaction (Figure 4.1 B), the 
disulfide cores of polyR-, RGD-, and non-modified g2P were reduced with TCEP, and 
added in 20% molar excess to the activated g4P-BMB conjugate. This final coupling 
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reaction was carried out overnight. Non-reacted g2P dendron species were removed by 
extensive centrifuge filtration (MWCO 10000, Millipore). Bowtie conjugates were 
subjected to 1H-NMR analysis, and bowtie spectra were compared to the polyR- and 
RGD-g2P spectra to verify coupling. Final dendrimeric bowtie species consisted of a 
non-modified g4P dendron coupled with a g2P dendron. Specifically, “non-dec-bowtie” 
consisted of no additional modifications, but polyR- and RGD-bowties presented either 
polyR or RGD peptides on the periphery of the g2P dendron. 
4.2.3 Evaluation of reaction progression 
Reaction completion status during bowtie generation was evaluated with 
Ellman’s reagent (5,5’-dithio-bis-(2-nitrobenzoic acid), DTNB). Briefly, g4P and 
unmodified g2P were reduced with 15mM TCEP and 10 mM EDTA in DPBS to give rise 
to thiol-containing hemispheric dendrons, which were then coupled with BMB as 
described above. To monitor the coupling reaction, 2 mL samples of dendrimer reagents 
or reaction mixtures were added at prescribed time points to 198 mL of an assay 
solution composed of 0.1 mM DTNB, 2.5 mM sodium acetate, and 50 mM 
tris(hydroxymethyl)aminomethane for a final volume of 200 mL in a 96-well plate well. 
Solutions were incubated for 5 min at room temperature, after which absorbance at 412 
nm was measured by SpectraMax M2 plate reader (Molecular Devices). Free thiol 
concentration was calculated from absorbance values and used to evaluate reaction 
status.  
4.2.4 Particle sizing and zeta-potential measurement 
The sizes of complexed miR-bowtie particles were determined using DLS. 
Complexes were prepared at an N/P ratio of 2. The selected dendrimer (500 µM in 
diethylpyrocarbonate (DEPC)-treated water) and miRNA (20 µM in DEPC water) were 
mixed at 1:12.5 volume ratio (1:25 for g4P), sonicated for 5 min, and incubated at room 
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temperature for 15 min. Then complexes were diluted to 0.175 µM (miRNA 
concentration) in water. The aqueous solutions were filtered through 0.20 µm filters 
(Sartorius stedim Biotech, Goettingen, Germany) to remove the dust. All the vials used 
during the experiment were carefully washed and sterilized. 
A commercialized spectrometer from Brookhaven Instruments Corporation (BI-
200SM Goniometer) was used to perform both static light scattering (SLS) and DLS over 
a scattering angular range of 20-120°. A vertically polarized, 33 mW solid-state laser 
(Brookhaven Instruments Corporation) operating at 635 nm was used as the light source, 
and a BI-TurboCo Digital Correlator (Brookhaven Instruments Corporation) was used to 
collect and process data. For a very dilute solution, the weight-averaged molar mass and 
the root mean-square radius of gyration (Rg) can be obtained from SLS data. By using a 
Laplace inversion program, CONTIN, the normalized distribution function of the 
characteristic line width was obtained which could be further converted into the 
hydrodynamic radius Rh by using the Stokes-Einstein equation D=kBT/(6πηRg), where D, 
kB, T, η are the translational diffusive coefficient, the Boltzmann constant, the absolute 
temperature, and the viscosity of the solvent, respectively. 
The zeta-potentials of miR-bowtie complexes were measured through 
electrophoretic light scattering experiments, which were performed by a ZetaPALS zeta 
potential analyzer (Brookhaven Instruments) with the samples described above. 
4.2.5 Gel retardation analysis 
To estimate the minimum of amount of dendrimeric bowties that can form 
complexes with certain amount of miRNA, gel retardation assay was carried out to 
visually analyze the unbound miRNA. Complex solutions were prepared as described 
above, with volume ratio of dendrimers and miRNA adjusted to the corresponding N/P 
ratio varied from 0 to 1.31. The solutions were diluted to 2 µM (miRNA concentration) in 
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DEPC water, and loading buffer was added to the solutions at 1:5 ratio. Samples 
containing miR-bowtie complexes were loaded in 3% agarose gel containing 1/10000 
GeneFinder™ nucleic acid dye prepared in 0.5x tris-borate-ethylenediaminetetraacetic 
acid (TBE), and electrophoresis was carried out at 110 V in 0.5x TBE buffer (pH 8.5). 
Bands were imaged by a Tanon-1600 Gel Documentation System (Tanon, Shanghai, 
China). 
4.2.6 Fluorescent dye exclusion assay 
To quantitatively evaluate the ratio of dendrimer to miR for complete 
oligonucleotide encapsulation, miR was complexed with varying molar ratios of 
dendrimeric bowties in DEPC-treated water for 2 min. Then GeneFinder nucleic acid dye 
was added in DPBS to a final volume of 50 mL for a GeneFinder dilution of 1:10000 and 
0.2 mM miR concentration. After 5 min incubation, GeneFinder-dyed Dendrimer-miR 
solutions were transferred in triplicate to a 96-well plate. The fluorescent signals 
(excitation: 489 nm, emission: 517 nm) resulting from GeneFinder binding non-
encapsulated miR were measured by a SpectraMax M2 plate reader (Molecular 
Devices). 
4.2.7 Transfection 
For the in vitro studies, HUVECs were subjected to reverse transfection before 
any further experiments. Cells were starved for at least 6 hours in no-serum ECM, then 
seeded in collagen-coated 24-well plates together with miR-bowtie complex solution in 
Opti-MEM with 2% FBS. After incubation for 8 hours at 37°C with 5% CO2, transfection 
media was replaced by 2% FBS Opti-MEM. Complexes (N/P ratio of 1.5) were prepared 
as above, and diluted to 0.175 µM (miR concentration) in 2% FBS Opti-MEM. 
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4.2.8 qRT-PCR primer design 
The primers for quantitative real-time polymerase chain reaction (qRT-PCR) 
assay were designed by online National Center for Biotechnology Information (NCBI) 
primer designing tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/), the product length 
is set between 100-250bp. The primers for SPRED1 and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were: SPRED1 forward, 5’-GCG ACT CAG GGA CAA AAT 
GGT GGT-3’; SPRED1 reverse, 5’-TCA AAA GCC CTA GCA TCA GCA GGA C-3’; 
GAPDH forward, 5’-GGT CGT ATT GGG CGC CTG GT-3’; GAPDH reverse, 5’-TAC 
TCA GCG CCA GCA TCG CC-3’. 
4.2.9 mRNA knockdown assay 
Twenty-four hours after transfection initiation (treatment groups included g4P, 
non-dec-bowtie, polyR-bowtie, and RGD-bowtie carrying either negative control miR or 
miR-126), total RNA of treated HUVECs was extracted using TRIzol (Invitrogen). Total 
isolated RNA (500-1000 ng) was reverse transcribed with TransScript First-Strand cDNA 
Synthesis SuperMix (Transgene, China, Beijing). The gene expression levels were 
analyzed using the SYBR Green real-time PCR method and quantified with the Bio-Rad 
CFX96 Real time PCR System (Bio-Rad). Primers for SPRED1 and GAPDH were all 
obtained from Sangon (China, Shanghai). SPRED1 gene expression values were 
normalized to GAPDH levels, followed by comparison of knockdown due to transfection 
of miR-126 or negative control miR within each transfection vehicle. Relative expression 
was calculated using the comparative CT method. The mean minimal cycle threshold 
values were calculated from triplicate reactions. 
4.2.10 Toxicity and proliferation 
After 40 hours incubation in 2% FBS Opti-MEM, media was removed, and the 
cells were fixed in 2% PFA and stained with 0.5 µg/mL DAPI for 10 min. Fluorescence 
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images were captured by an IX71 fluorescence microscope (Olympus, Japan), and the 
number of cells in each well was counted. 
4.2.11 Tube formation 
Forty hours after transfection media replacement with fresh media, cells were 
detached and counted. Ten thousand cells from each treatment group were re-
suspended in ECM supplemented with 5% FBS and plated onto Matrigel films in 96-well 
plates. Cells were incubated for 6 hours and imaged under bright-field microscopy. Tube 
length was quantified by ImageJ software analysis.183 Tube formation experiments were 
performed three times. 
4.2.12 Statistics 
Quantitative results were presented as means ± standard error of measurements. 
Where appropriate, statistical comparisons were performed with one-way ANOVA 
followed by Fisher’s least significant difference post-hoc test. All statistical tests were 
conducted using IBM SPSS 20.0.0 statistical software. The level of significance was 
denoted by *, **, and ***, denoting p values of <0.05, <0.01, and <0.001, respectively. 
4.3 Results 
4.3.1 Synthesis of dendrimeric bowtie conjugates 
After decoration of g2P dendrimers with ligands (Figure 4.1 A), the dendrimers 
were cleaved with TCEP and coupled with similarly cleaved g4P dendrons (Figure 4.1 B), 
giving rise to a bowtie structure containing two distinct hemispheric regions. The 
conjugates were termed “non-dec-bowtie”, “polyR-bowtie”, and “RGD-bowtie”.  
We monitored the dendron coupling process by evaluating the reduction of g2P 
and g4P with TCEP, and the coupling of the thiol-containing dendrons with BMB. 
Ellman’s reagent, DTNB, was employed to relatively quantify the remaining free thiol 
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groups such as those generated and consumed in our bowtie conjugation scheme 
(Figure 4.2). By sampling our reaction mixture at various stages, we confirmed with 
statistical significance the cleavage and coupling of dendrimers of dendrimeric bowties. 
Specifically, only 3.7 ± 0.6% of the cleaved g4P dendrons remained unmodified after 30 
min, whereas the free thiols from the second infusion of cleaved dendrons remained 
unmodified for a longer period: 54.5 ± 5.1% after 30 min and 1.3 ± 0.6% overnight. The 
modification of cleaved g4P dendrons with BMB proceeded at a faster overall rate than 
the coupling of BMB-g4P conjugates with cleaved dendrons: whereas 96% of g4P 
sulfydryl groups conjugated to BMB within 30 min, only 46% of free thiols from the 
second infusion of cleaved dendrimers converted within a matched time frame. This was 
likely due to differences in the ratios between sulfydryl and maleimide groups; our 
reaction mixture between cleaved g4P dendrons contained a free thiol:maleimide ratio of 
1:20, whereas the subsequent BMB-g4P reaction with cleaved dendrons contained a 
stoichiometric ratio of 1:1.2. Also, the relatively small size of free BMB (248.23 Da) may 
have contributed to an increased reaction rate compared to the larger BMB-g4P 






Figure 4.2. Progression of coupling reaction. Indicated by the generation and consumption of 




Further confirmation of the coupling between cleaved g4P and g2P dendrons 
was conducted by examining the 1H-NMR spectra of g4P, decorated g2P dendrimers, 
and final bowtie conjugates (Figure 4.3). The representative PAMAM peaks occur in the 
2.6 to 2.9 ppm range and the polyR and RGD peaks occur in the 1.5 to 2.0 ppm range 
(in both cases due to the alkene protons present in the arginine side chain). Qualitative 
comparison between the g2P conjugate and the bowtie spectra indicate a decrease in 
the area of the arginine peaks, correlated with an increase in the area of the PAMAM 
peaks. This analysis confirms the coupling between the thiols of the cleaved g4P and 






Figure 4.3. Comparison among g4P, decorated g2P, and bowtie NMR spectra. The decrease 




4.3.2 Encapsulation of miR by dendrimeric bowtie 
We characterized the complexation capacity of miR by dendrimers to determine 
the maximum payload. We first evaluated this by dye exclusion assay, as measured by 
fluorescent plate reader (Figure 4.4 A). As the N/P ratio increased from 0 to 0.33, the 
amount of non-encapsulated miR decreased as evidenced by the decreased 
fluorescence intensity. When N/P ratios were greater than 0.33, the change in 
fluorescence intensity decreased, indicating that the maximum loading capacity of 
dendrimeric bowties with miR corresponded with an N/P ratio of approximately 0.66. 
To corroborate these findings, we performed gel electrophoresis experiments 
with similar N/P ratios (Figure 4.4 B). For ratios less than 0.33, bands present in the gel 
indicated that the amounts of dendrimer in the systems were insufficient for complete 
miR encapsulation. In contrast, the lack of bands in lanes where the N/P ratio was 
greater than or equal to 0.33 signified the total encapsulation of miR. This trend was 
similar to that observed in the fluorescent dye exclusion assay. Loading capacity of miR 






Figure 4.4. Evaluation of the dendrimeric vehicle encapsulation capacity. Measured by (A) 
fluorescent dye exclusion and (B) gel retardation. The N/P ratio that maximized payload and 




4.3.3 Physical characterization of dendrimer conjugates 
The particle sizing spectra as measured by SLS at 90o is displayed in Figure 4.5 
A. Average radii (radius of gyration) and zeta potentials of particles formed by miR-
encapsulated dendrimers are presented in Figure 4.5 B. Particle radii ranged from 96 to 
108 nm, indicating the occurrence of dendrimer aggregation. Zeta potentials ranged from 






Figure 4.5. Dendrimer sizes. (A) DLS particle size spectra. (B) Summary of particle radius and 




4.3.4 Dendrimer conjugate type affects cell viability and transfection efficacy 
Cells were treated with dendrimeric bowties and g4P loaded with non-targeting 
miR to evaluate toxic effects of the delivery systems. We found that compared to non-
treated cells, g4P and non-dec-bowties significantly reduced HUVEC cell number by 
76.2 ± 3.3% (p=0.032) and 74.7 ± 4.2% (p=0.024) of non-treated group size, 
respectively (Figure 4.6 A). In contrast, treatment of cells with bowties polyR- or RGD-
bowties loaded with non-targeting miR mimic exhibited no statistically significant 






Figure 4.6. Cytotoxic and proliferative effects of dendrimers. (A) Cytotoxicity effects of 
dendrimeric vehicles on HUVECs. G4P and nondec-bowties were both toxic, whereas neither 
polyR-bowtie and RGD-bowtie affected cell population. (B) Proliferative effects of miR-126-loaded 
vehicles. RGD-bowtie was the only group to increase proliferation, whereas g4P decreased cell 




We then treated cells with miR-126-loaded dendrimers for 8 hours followed by 40 
hours incubation and measured proliferation by cell counting. Only transfection mediated 
by RGD-bowtie demonstrated a significant proliferative effect (Figure 4.6 B). Compared 
to non-treated cells, transfection by loaded g4P caused a statistically significant loss in 
cell numbers of 60.8 ± 7.1 % (p=0.050). This result is consistent with the g4P loaded 
with non-targeting miR. Transfection by non-dec- and polyR-bowties demonstrated no 
significant negative or beneficial effect on cell number: just 75.1 ± 3.7 % (p=0.187) and 
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93.0 ± 9.8 % (p=0.698), respectively, compared to non-treated groups. In contrast, miR-
126 transfection mediated by RGD-bowties resulted in a statistically significant increase 
of 153.8 ± 5.8% (p=0.012) in cell number.  
4.3.3 HUVEC tube formation as a function of dendrimer type 
We evaluated the ability of miR-126-loaded dendrimers to induce tube formation 
in HUVECs (Figure 4.7). When plated on matrigel films, tubes formed by cells treated 
with miR-126-loaded g4P were statistically shorter: only 59.9 ± 1.6 % (p=0.036) as long 
as tubes formed by non-treated cells. Likewise, treatment with miR-loaded non-dec-
bowties failed to show an increase in tube length. However, both polyR- and RGD-
bowties loaded with miR-126 significantly increased tube formation: compared to non-
treated cells, polyR-bowtie-treated cells formed 160.5 ± 8.4 % (p=0.004) tube length and 
RGD-bowtie-treated cells almost doubled tube length to 191.5 ± 9.6 % (p=0.0003) of 






Figure 4.7. Tube formation analysis as a result from transfection of miR-126 or negative 
control miR with dendrimeric vehicles. G4P-mediated transfection failed to induce tube 
formation of HUVECs, whereas both polyR- and RGD-bowtie enhanced tube formation when 
delivering miR-126. Neither polyR- nor RGD-bowtie loaded with negative control miR induced 




To evaluate if the increase in tube formation was elicited by cell-material 
interactions from polyR- or RGD-bowtie, or if it were due to miR-126 transfection, we 
transfected HUVECs with negative control miR. We found that neither treatment groups 
exhibited a significant change in tube formation compared to non-treated cells (Figure 
4.7). 
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4.3.6 Molecular analysis of dendrimer-mediated knockdown 
To further evaluate transfection efficacy of miR-loaded dendrimers, we measured 
the presence of SPRED1-encoding mRNA, the target of miR-126, in treated and non-
treated cells (Figure 4.8). Of note was that polyR-bowtie- and g4P-mediated transfection 
showed significant decreases in SPRED1 mRNA: g4P and polyR-bowtie dropped 
SPRED1 mRNA levels to 50.4 ± 10.7% (p=0.046) and 49.7.0 ± 3.0% (p=0.044) 
compared to non-treated cells. Our experiments suggested a trend for RGD-bowtie-
mediated transfection to knock down SPRED1 mRNA (67.1 ± 6.6%, p=0.162), and non-
dec-bowtie dendrimers did not knock down the presence of SPRED1 mRNA. However, 
decoration of dendrimeric bowties enhanced knockdown of SPRED1 mRNA: compared 
to cells treated with non-dec-bowties, dendrimeric RGD-bowties and polyR-bowties 






Figure 4.8. Efficiency of dendrimeric vehicle-mediated transfection of miR-126. Compared 
to nontreated control groups, only g4P and polyR-bowtie downregulated SPRED1, a target of 
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miR-126. Compared to no-dec-bowtie, the other vehicles—including RGD-bowtie—decreased the 





Dendrimers have been explored as drug delivery agents because they present a 
stable, well-defined nanoscale architecture with a tunable number of reactive terminal 
groups.174-176 The efficacy of “naked” siRNA therapy has been due to circulating RNase 
A-type nucleases and rapid renal clearance.184, 185 Dendrimers have proven protective 
against degradation by RNase,37 which—coupled with their functionalizable surface 
groups—intimates their application for RNAi therapeutics. However, the traditional 
dendrimer design potentially faces limited application: although altering ligand density is 
a feasible way to tune particle uptake, hemispheric selectivity of ligand conjugation to 
simultaneously spatially control both the density and number of ligands or RNA-binding 
sites is virtually non-existent. To address this insufficiency, we proposed a bowtie design 
that features two regions of either locally dense ligands or RNA-binding amines.  
Synthetic schemes for generating dendrimeric bowties can be divergent186, 187 or 
convergent, i.e. grown from a “seed” dendrimer that features ab initio orthogonally 
reactive terminal groups or generating a final molecule from unique dendrimers 
developed a priori. Convergent synthesis can feature either the coupling of dendrons 
featuring unique reactive groups at the core, such as that rely on click chemistry,188 or 
the cleaving and coupling of identical functional groups, such as dendrimers with 
reducible disulfide cores.189, 190 Divergent synthesis can be problematic in that not all 
terminal groups may be modified at each synthetic step. However, cystamine-core 
PAMAM dendrimers of several generations are commercially available and feature 
readily functionalizable reactive terminal amines. One other advantage of these 
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dendrimers is the availability of thiol-reactive coupling agents that minimize the reaction 
incidences of non-unique dendrons (as opposed to re-oxidation in the presence of air); 
by reacting the coupler with one dendron type before adding the second species, the 
synthesis of homogenous bowties is avoided. The method presented here generates 
disulfide-core dendrimers decorated with desired terminal groups before reduction of the 
disulfide bond and convergent bowtie synthesis by bismaleimido coupling. 
It is seen that the RGD-bowtie and non-decorated bowtie (but not polyR-bowtie 
or PAMAM) showed reduced zeta potential but were still in the negative range. These 
results are considered reasonable for the following reasons. First, we chose to use 
minimum amounts of dendrimeric carrier to complex with RNA to test the carrier under 
high loading capacity. Second, this result actually matches with the structure of the 
carrier, as aspartic acid (in RGD)—which is speculated to be on the surface of the 
nanocomplex—is negatively charged, as are the hydrolyzed maleimide groups (which 
converted to carboxylic acids) on the peptide-modified dendrimeric bowties. PolyR may 
provide more positively charged groups that balanced the negative charges on bowtie 
surface.  
Our studies191 demonstrated the superiority of bioactive ligand-decorated 
dendrimeric bowties compared with both non-decorated bowties and g4P in preventing 
cell toxicity under experimental conditions of 0.175 mM miR and N/P ratio of 1.5. 
Whereas both g4P and non-dec-bowtie were detrimental to cell number, neither polyR-
bowtie nor RGD-bowtie materials exerted cytotoxicity. The toxic effects that dendrimers 
exhibit are generally attributed to the cationic charges of the terminal amines, which can 
contribute to membrane destabilization192 and apoptotic pathway activation.193 Therefore, 
it is important to consider such electrostatic interactions when evaluating vehicle 
performance, and in our dendrimeric bowties were structurally different from g4P: each 
bowtie bore half of the charged amines as compared to g4P, which featured higher local 
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charge density. But despite containing half of the positive surface charges as g4P, it was 
apparent that the existing charges on non-dec-bowtie were sufficient to induce similar 
toxic effects. In contrast, the lack of cytotoxicity exerted by either polyR- or RGD-bowtie 
indicated the beneficial consequence of surface peptide decoration-mitigated toxicity. By 
conjugating peptides to an otherwise cytotoxic backbone, the overall concentration of 
PAMAM terminal amine charges within one vehicle is decreased, which may ameliorate 
toxic interactions such as membrane destabilization. Furthermore, peptides on 
dendrimer surfaces may activate internalization mechanisms different from those elicited 
by PAMAM surface charges. 
Characterizing the effects of vehicle type on cell viability provided preliminary 
information on the suitability of dendrimeric bowties for transfection, but we were 
interested in examining the further pro-angiogenic effects of the decorated bowtie-
mediated delivery versus delivery mediated by g4P and non-dec-bowtie. Both g4P and 
non-dec-bowtie were unable to induce cell proliferation or tube formation, perhaps due to 
their relatively high cytotoxicity that may have counteracted any proliferative effects. On 
the other hand, PolyR-bowtie knocked down SPRED1 by half and successfully induced 
tube formation despite having no effect on proliferation. Considering that the polyR-
bowtie exerted no detrimental effects on cell viability, a proliferative/tubulogenic-
decoupled interaction may be taking place between the material and signaling or 
translational pathways that remains to be explored. The possibility of distinctive effector 
pathways was further demonstrated by miR-126-loaded RGD-bowtie, which both 
induced cell proliferation and tube formation. Although RGD-bowtie lacked statistical 
significance in its knockdown of SPRED1 by a third compared to non-treated cells, we 
did find that RGD decoration enhanced SPRED1 knockdown significantly compared to 
non-dec-bowtie. As others have demonstrated that RGD induces cellular 
internalization,40, 178, 194-196 it is entirely possible that in our studies, the RGD-bowtie 
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mediated uptake of miR-126 improved proliferation and tube formation through an 
independent non-SPRED1 pathway. The mRNA targets of miR-126 include CRK,197 
CXCL12,198 HOXA9,199 PIK3R2,200 TOM1,201 and SPRED1.200 The last is a negative 
regulator of MAPK and PI3K signaling, and served as a surrogate for ascertaining 
transfection efficacy in our study. We also failed to find significant regulation of PIK3R2 
mRNA in any treatment groups. Another possible mechanism for the angiogenic effects 
of RGD-bowtie is that, as RGD is part of the recognition sequence that binds integrin,202 
extracellular interactions from the tethered RGD may have contributed to downstream 
results through differential gene expression.203 However, neither polyR- nor RGD-bowtie 
materials alone were found to increase tube length, indicating that tube formation was 
dependent on at least miR-126 internalization, though vehicle type may compound 
angiogenic effects. The ability of g4P to downregulate SPRED1 mRNA while exerting 
deleterious downstream effects was a striking demonstration of its unsuitability as a 
transfection agent in pro-angiogenic applications. 
There has been a burgeoning field of miR discoveries in the last several years, 
and research toward application is in close suit. The miRs 27b,204 92a,205 126,200 130a,206 
132,207 and 210200 among others have been reported to regulate angiogenesis.208 
Additionally, miRs associated with cardiac development, endothelial cell proliferation, 
vascular integrity, and CM and vascular smooth muscle cell differentiation have been 
identified.15-17, 209 The promise of therapeutic applications exists in exploiting the 
endogenous RNAi machinery by delivery of effective levels of miRs or antagomirs to the 
intended cell types. The field of delivery nanovehicles for miRs, however, is largely 
undeveloped. Future in vivo studies are warranted to investigate treatment with miR-
loaded bowties to rescue the heart in a rat MI model.  
Taken together, RGD-bowtie functioned as a potential miR-delivery agent for 
angiogenic application by significantly enhancing cell proliferation and tube formation of 
 80 
endothelial cells without contributing to cytotoxicity. Our study could have wide-ranging 
implications for developing new transfection reagents for primary cells as well as for 
promoting angiogenesis by enhancing endothelial proliferation and tube formation, which 
would be considered a significant and applicable accomplishment. As a cardiology lab, 
we are especially interested in these functions as a potential therapeutic system to treat 
the infarcted heart.  
Multi-functional dendrimeric bowties are substantially versatile in regards to size, 
shape, and regio-selectivity of terminal chemical groups. In the field of RNAi therapeutics, 
they may prove to be superior transfection agents due to the high concentration of miR- 
and siRNA-binding groups and targeting groups that they simultaneously offer. Our 
overall objective in this study was to present the design and functionality of a novel bi-
functional dendrimeric conjugate, one half consisting of a cationic PAMAM dendron 
capable of binding miR, and the other half decorated with cell-targeting peptide ligands. 
We presented a facile synthetic scheme for generating our bowtie construct and 
demonstrated successful knockdown of a targeted SPRED1 mRNA with miR-126. As it 
stands, these dendrimeric bowties were substantially more effective in inducing 
downstream effects than conventional g4P while exhibiting much greater biocompatibility. 
Our study demonstrates the paradigm to synthesize ligand-decorated dendrimeric 
bowties with defined spatial structures and this model system could lay the groundwork 
for development of a miR-based therapy for myocardial and peripheral ischemic 




THERAPEUTIC EFFECTS OF EXOSOMES FROM HYPOXIC CARDIAC 





Cardiovascular disease is the leading cause of morbidity and mortality in 
developed nations, and acute MI is the major subgroup, with an estimated 1.1 million 
Americans suffering MI alone.49 Beyond the acute treatment of restoring blood flow to 
the infarct, subsequent measures focus on improving the contractility of the remaining 
tissue. The damaged, relatively non-regenerative myocardium undergoes a 
degenerative process leading to heart failure. Consequently, the annual financial cost of 
cardiovascular totaled $315.4 billion in 2010, and costs are expected to grow to $918 
billion annually by 2030 when 43.9% of the population is expected to suffer from CVD.49 
Cell-based therapies to treat the heart—including injection of stem cells from 
various sources—have yielded mixed results in several species.41-44 Cardiac progenitor 
cells, a small population of stem-like cells residing in the heart, are of interest as they 
only differentiate in to cardiac lineages and can be isolated by tissue biopsy. 
Researchers have induced differentiation of stem cells into various cardiac cell types, 
and observed that cell secretion changes in response to alterations in extracellular 
conditions.210-215 However, whether stem cells contribute to the cardiac response through 
differentiation or paracrine signaling—or a combination of the two—is still unknown. 
Despite the moderate benefit in stem cell therapy, major hurdles remain, including 
immunogenicity, toxic engraftment environment, and temporal constraints in patient-
specific cell expansion. 
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MicroRNAs have been known to function in intracellular gene regulation, but in 
the past decade have been discovered to circulate in mammals.216, 217 Since then, stable 
miRs have also been discovered in urine, saliva, semen, breast milk, and cerebrospinal 
fluid.217-220 Differential miR profiles were found in biofluids based on pathology, leading to 
interest in the development of disease biomarkers.120, 130, 221 These profiles have already 
been explored for a range of conditions, including cancer, diabetes, and CVDs.120, 222, 223 
The discovery of stable circulating miR was met with some surprise, as 
circulating nucleases would be expected to degrade extracellular miR.126 However, 
various protective carriers for extracellular miR have been observed: membrane-derived 
vesicles (apoptotic bodies, microvesicles, and exosomes), high-density and low-density 
lipoproteins, and proteins (especially from ribonucleoprotein complexes).126, 209, 217, 222 
Recent efforts have been made to explore the endogenous function of circulating miRs, 
especially in intercellular gene regulation.217, 224 Originally considered cell debris, 
membrane-derived vesicles were more appropriately characterized in 1987,121 and cell-
cell transfer of exosomes observed in 2002,122, 123 but miR encapsulation by exosomes 
was not verified until 2007.124, 125 Interestingly, the miR signatures are unique among the 
different carriers,126 and even between carriers and parent cells, suggesting regulated 
export of miRs.15, 126, 128 Most cells secrete exosomes; those verified include platelets,222, 
225 lymphocytes,224 and adipocytes,226 and, muscle,120, 135, 227 tumor,228, 229 glial,230 and 
stem cells.48, 138, 140, 141, 231  
In this report, we generated exosomes from CPCs exposed to hypoxic  and normoxic 
conditions for 3 hr or 12 hr and explored the effects of these exosomes on cardiac cells in vitro. 
We found that exosomes from CPCs subjected to hypoxia for 12 hourr induced significantly more 
tube formation and reduced fibrotic gene expression as compared to exosomes from normoxic 
CPCs. We also analyzed secreted miR via array and identified several miRs upregulated by 
hypoxia 12 hr exosomes. Using empirical data and statistical transformation processes, we 
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developed a computational model of miR content to predict the effects of 3 hr exosomes from 
hypoxic and normoxic CPCs. Finally, we identified co-varying miR clusters that may lead to 
future bio-inspired therapeutics. 
5.2 Materials and Methods 
5.2.1 Media components 
The media that was used for the fibroblasts consisted for 10% FBS, 1% L-
glutamine, 1% penecillin, and 1% streptavidin, and DMEM basal media. For DMEM 
quiescent media, FBS was reduced to 2%. The culture media that was used for the 
cardiac microvascular endothelial cells (CECs) consisted of animal cardiac endothelial 
cell basal media, 2% FBS, 1% L-glutamine and 1% antibiotic/amniotic and 0.1% 
endothelial cell growth supplement. For CEC quiescent media, FBS was reduced to 
0.04%. The CPC culture media, Ham’s F-12 basal media was used along with 10% FBS, 
1% penecillin, 1% streptavidin, 1% L-glutamine, 0.1% Leukemia Inhibitory Factor (LIF), 
and 10% fetal bovine growth factor. For CPC quiescent media, no FBS was used and 
1% ITS was added. For CPC treatment media, no FBS or LIF was used and 1% insulin-
transferrin-selenium (ITS) was added.  
5.2.2 Exosome generation  
Cardiac progenitor cells were grown to 90% confluence and quiesced for 12 hr. 
Plated cells were subjected to normoxic or hypoxic conditions for 3 hours or 12 hours. 
To generate hypoxic conditions, cells were transferred to an incubator chamber (Billups-
Rothenberg MIC-101) and flushed with hypoxic gas mixture (95% N2, 5% CO2). After 
conditioning, the media was subjected to sequential centrifugation (Optima XPN-100 
ultracentrifuge; Beckman Coulter SW 41 Ti rotor) at 10,000 x g for 35 min to remove cell 
debris and 100,000 x g for 70 min., followed by two washings in PBS (100,000 x g, 70 
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min.). The exosome pellet was isolated and the protein content of the exosome 
suspension was analyzed by Micro BCA Protein Assay kit (Thermo Scientific Pierce 
23235) according to manufacturer’s instructions.  
5.2.3 Secreted miR analysis 
miR was isolated from conditioned media with the miRVANA PARIS kit 
(Invitrogen AM1556M) according to manufacturer’s protocol. The miR solutions were 
then analyzed (Agilent 2100 Bioanalyzer) for size, quality, and quantity of miR. Following 
characterization, miR was subjected to analysis via Affymetrix MultiSpecies MicroRNA 
GeneChip array. Data were analyzed in Affymetrix Expression Console to determine 
levels of miR upregulation. 
To evaluate levels of upregulated miR in exosomes, exosomal miR was isolated 
with the miRVANA PARIS kit and cDNA generated via NCode miRNA First-Strand cDNA 
Synthesis Kit (Invitrogen MIRC-50) according to manufacturer’s protocol. cDNA samples 
were then subjected to qRT-PCR and relative mRNA levels ascertained by comparative 
CT method. The primers for CTGF and GAPDH GAPDH were: CTGF forward, 5’- AAT 
GCT GTG AGG AGT GGG TG-3’; CTGF reverse, 5’- TGG CTC GCA TCA TAG TTG 
GG-3’; GAPDH forward, 5’- CCA GCC CAG CAA GGA TAC TG-3’; GAPDH reverse, 5’- 
GGC CCC TCC TGT TGT TAT GG-3’. 
5.2.4 Flow cytometry on exosomes 
Pooled exosomes were incubated with 1 uL sulfate-aldehyde latex beads 
(Invitrogen A37304) for 2.5 hr at 37 C, after which 100 mM glycine in 10% goat serum 
was added to quench the reactive groups and block. Exosome-bead complexes were 
centrifuged (4,000 x g, 5 min) and washed with 1% bovine serum albumin (BSA) in PBS. 
Complexes were resuspended and incubated with mouse anti-rat CD 1° antibody (BD 
Biosciences 551808) for 12 hr at 4 °C. Complexes were washed in 1% BSA/PBS and 
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incubated in Alexa Fluor 488 goat anti-mouse IgG (H+L) antibody (Invitrogen A-11001). 
After incubation (2 hr at 37 °C), complexes were washed twice and subjected to flow 
cytometry (BD Biosciences BD LSR II), where at least 50,000 events were collected. 
5.2.5 Transmission electron microscopy 
Exosome pellets were isolated. The samples were prepared by a negative 
staining method using 1% phosphotungstic acid. 5 µl of the sample was deposited onto 
carbon-coated 200 mesh cooper grids that have been treated by glow discharge. After 5 
minutes, the grid was dragged on a peiece of filter paper to remove excess liquid on grid. 
5 µl of 1% aqueous phosphotungstic acid (PTS, ph6.5) was deposited onto the grid 
before sample on grid was dried. After 30 seconds, the grid wad dragged on a piece of 
filter paper to remove the PTA on the grid. In the end, the grid was left to air-dry. The 
samples were then imaged using the JEOL JEM-140 0 transmission electron 
microscope.  
5.2.6 Cellular uptake of exosomes 
Exosomes were stained with calcein (2 uM final concentration) for 30 min at 
room temperature, followed by two washes in PBS (100,000 x g, 70 min). Pellets were 
then passed through 0.20 um filters. Rat cardiac fibroblasts and endothelial cells were 
treated with the stained exosomes (1 mg/mL) for 12 hr and washed before being 
trypsonized and subjected to flow cytometry (Imagestream X Mark II), where 10,000 
events were collected. Images were analyzed by Amnis IDEAS image analysis software 
using spot count and channel intensity wizards. 
5.2.7 Tube formation 
Rat primary CECs (CellBiologics R2111) were plated on gelatin-coated 12 well 
plates. Following quiescence for 12 hr, cells were then treated with 0.01, 0.1 and 1 
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mg/ml hypoxic or normoxic exosomes for 24 hours. The cells were then lifted and 
counted so that 10,000 cells from each treatment group were plated onto 30 ul Geltrex 
(Invitrogen A1413202) thick gels in 96-well plates. The cells were then incubated for 6 
hours and stained with 2 µM calcein in PBS.  Cell groups were imaged with a fluorescent 
microscope (Olympus IX71) and the tube length was quantified using ImageJ software 
analysis. 
5.2.8 Rat cardiac fibroblast isolation 
Excised hearts from adult male Sprague-Dawley rats were minced and subjected 
to trypsin digestion (1 mg/mL in HBSS-, 4 C, 6 hr), followed by collagenase digestion 
(0.8 mg/ml in HBSS-, 37 C, 15 min). Digestion solutions were quenched with culture 
media and cell suspension passed through a 100 um filter. Cells were pelleted and 
plated for 3 hr to allow adherence of fibroblasts before washing plates to remove non-
fibroblasts. 
5.2.9 TGF-β stimulation  
Fibroblasts were quiesced for 12 hr and treated with 0.1 mg/ml exosome for 12 
hr before the addition of TGF-β (2 ng/ml final concentration) for 12 hr. Cell mRNA was 
isolated via Trizol reagent (Invitrogen 15596-026) according to manufacturer’s 
instructions. cDNA was generated via M-MLV Reverse Transcriptase (Invitrogen 28025-
013) and qRT-PCR (Power SYBR Green, Invitrogen 4368708) was performed to 
evaluate CT levels. Relative expression was calculated using the comparative CT 
method. The mean minimal cycle threshold values were calculated from triplicate 
reactions. 
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5.2.10 Principle component and partial least squares regression analysis 
Principle component analysis was applied to normalized miR array data (3 hr or 
12 hr generation duration; normoxic or hypoxic conditions) to evaluate data along three 
principle components. Then Simca-P (UMetrics) software was used to establish 
relationships between miR levels (signals) responding to cues (exosome generation 
conditions) and responses (tube formation and connective tissue growth factor (CTGF) 
mRNA levels). Variable Importance of Projection (VIP) were calculated to determine 
which signals have the greatest projection/contribution towards a phenotypic outcome. 
By identifying the VIPs, the number of miRs needed to evaluate was reduced from 378 
to 100. A new model was produced by iteration using the same response matrix values. 
Finally, another PLSR model was created trained on the 7 miRs confirmed by qRT-PCR. 
Goodness of prediction was tested using a bootstrapping approach; cross-validation was 
performed by omitting an observation, then using the calculated weighted coefficient 
matrix to predict response values without those removed observations.  This procedure 
was repeated until every observation had been excluded exactly once.  Then 
predictability was determined using root mean square error between predicted and 
experimentally observed values. 
5.2.11 Statistics 
All statistics were prepared with Graphpad Prism software. Results are reported 
as average±SEM. 
5.3 Results 
5.3.1 Characterization of isolated exosomes 
To verify that hyopoxic and normoxic CPCs release exosomes media was 
subjected to high-speed centrifugation and exosome fraction was collected. We bound 
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exosomes to reactive sulfate-aldehyde latex beads and incubated the complexes with 
antibody against CD9, an exosomal surface marker. Flow cytometry revealed the 
exosome-bead complexes as CD9+, whereas the negative controls—beads alone and 
antibody-incubated beads—were negative for CD9 (Figure 5.1 A). Transmission electron 
microscopy confirmed exosome isolation, with visual confirmation of vesicles with 
average diameter of 102.0±3.1 nm and 96.1±6.1 nm for exosomes from normoxic or 
hypoxic exosomes, respectively (Figure 5.1 B). We measured total small RNA and 
protein levels in exosomes from both hypoxic and normoxic CPCs, and confirmed that 






Figure 5.1. Characterization of isolated exosomes. A) Flow cytometry validated presence of 
CD9+ exosomes. B) Transmission electron microscopy imaged exosomes generated in normoxic 
and hypoxic conditions (scale bar = 100 nm). No difference was observed in (C) small RNA or (D) 





5.3.2 Evaluation of cellular uptake of exosomes 
We next determined whether cardiac cell types of interest could internalize 
exosomes. To test this, we treated cardiac endothelial cells and cardiac fibroblasts with 
fluorescent calcein-stained exosomes for 12 hr, and imaged cells quantitatively with 
ImageStream flow cytometry (Figure 5.2 A, B). Internalization of exosomes was 
confirmed visually by the presence of intracellular punctate fluorescence. In addition, we 
evaluated if rates of internalization were dependent on exosome type. Analysis of 
number of spots per cell revealed no difference in uptake between exosomes from 
hypoxic or normoxic CPCs in either cell type (Figure 5.2 C, D). Furthermore, no 
difference was observed in average fluorescence intensity per cell between exosome 






Figure 5.2. Cardiac cells internalize exosomes. Calcein-stained exosomes were internalized 
by both CECs (A) and fibroblasts (B). There was no difference in uptake of exosomes by either 




5.3.3 Effects of exosomes on endothelial tube formation 
We sought to evaluate whether internalization of exosomes could induce 
endothelial tube formation. Cardiac endothelial cells were treated for 24 hrs with 
exosomes from hypoxic or normoxic CPCs and then plated on Geltrex prior to imaging 
(Figure 5.3 A). While exosomes from normoxic CPCs had no significant effect on tube 
formation, exosomes from hypoxic CPCs significantly enhanced formation of tube-like 
structures (Figure 5.3 B).  This response was dependent on exosome dose, plateauing 
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at 0.1 mg/mL with a 2.24±0.24-fold increase in tube formation. Disruption of exosomes 





Figure 5.3. Exosomes from hypoxic CPCs enhance endothelial tube formation. Tube-like 
structures were imaged (A) and quantified (B). While exosomes from normoxic CPCs did not 




5.3.4 Mitigation of fibroblast stimulation by exosomes 
To investigate the potential effects of exosomes on fibrosis, we treated rat 
cardiac fibroblasts with either exosomes derived from normoxic or hypoxic CPCs prior to 
stimulation with the TGF-β. Levels of mRNA encoding connective tissue growth factor 
(CTGF) were determined by qRT-PCR (Figure 5.4). As expected, CTGF mRNA levels 
increased 3.6±0.28-fold upon TGF-β stimulation. We observed no significant decrease in 
CTGF mRNA levels in response to treatment with exosomes from normoxic CPCs, but 
detected a significant decrease in cells treated with hypoxic exosomes to only 2.1±0.14-






Figure 5.4. Exosomes from hypoxic exosomes mitigated fibroblast stimulation.TGF-β 




5.3.5 Evaluation of miR exosome contents 
We next evaluated the change in the miR secretome of CPCs in response to 
hypoxic conditions. We isolated the small RNA fraction of CPC conditioned media (3 and 
12 hour, normoxic and hypoxic) and performed Affymetrix GeneChip miR array. We 
found 11 miRs upregulated 2-fold or more due to hypoxic conditions at the 12 hour time 
point. Conducting qRT-PCR on the small RNA isolated from pooled exosomes, we 
validated the upregulation in hypoxic exosomes of seven of the 11 miRs upregulated in 
hypoxic conditioned media (Figure 5.5 A). Conducting a literature review for these seven 
miRs and their reported functions revealed correlative and relationships between the 






Figure 5.5. Identification and review of upregulated exosomal miRs. A) qRT-PCR identified 
seven miRs upregulated in exosomes generated by hypoxic CPCs. B) The miRs have been 




5.3.6 Statistical modeling of exosomal miRs and physiological responses 
Principle component analysis was applied to normalized data from the microarray 
to help group miR that co-vary based on the treatment condition.  Exosomes treated with 
normoxia or hypoxia were examined and their miR levels and fold changes were input 
into PCA.  The first PC clearly separated the fold change differences from the other 
signals.  PC2 was the normoxia/hypoxia axis.  However, 4 distinct clusters of miRs were 





Figure 5.6. PC and PLSR analysis of upregulate miRs and physiological functions. A) PC 
analysis discovered 4 unique clusters of miR that associate with either hypoxia or normoxia. B) 
PLSR of 3 or 12 hour hypoxia matched with outputs of tube formation (angiogenesis) and CTGF 
(fibrosis).  Top 100 VIPs were used to make the new model to determine which miRs contributing 
to one outcome or the other. Clear covariance of 12 hr hypoxia with tube formation and 12 hr 





Using the software Simca-P (UMetrics), PLSR first considered the entire dataset 
and established a relationship between miR levels as signals responding to the cues of 3 
or 12 hr normoxia or hypoxia treatment, and the responses of tube formation, as a 
surrogate for angiogenesis, and CTGF levels, as a surrogate for fibrosis. Then the VIP 
(Variable Importance of Projection) were calculated to determine which signals (miRs) 
have greatest projection/contribution towards a phenotypic outcome. PLSR analysis also 
can identify the most important miR signals for a response outcome by calculating VIP 
using a weighted sum of squares of the coefficients calculated for a signal, such that 
those signals projecting strongly either positively or negatively with either CTGF or tube 
formation response, are highly ranked. By identifying these VIPs, the amount of data 
needed to capture and predict a specific response can be reduced from the 378 miR 
down to the top 100 VIPs, and a new model was made using same response matrix 
values.  Scores plot shows 12 hr hypoxia and 12 hr normoxia plotted on only one 
principle component (PC) that was calculated (Figure 5.6 B); this was due to these top 
signals, again projecting most towards the key driving cue, hypoxia vs. normoxia.  Clear 
separation of normoxia and hypoxia in the scores plot match the separation of tube 
formation and CTGF in the response loadings plot.  More, fibrosis (CTGF) co-varies with 
normoxia cues and tube formation co-varies with hypoxia cues.  
A new PLSR model was created trained on the 11 miR confirmed by qRT-PCR 
from preliminary data discussed in Aim 1 that were matched to physiologically relevant 
outcomes for cardiac function post-MI (Figure 5.7). Goodness of prediction was tested 
using a bootstrapping approach; cross-validation was performed by omitting an 
observation, then using the calculated weighted coefficient matrix to predict response 
values without those removed observations.  This procedure was repeated until every 
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observation had been excluded exactly once.  Then predictability was determined using 
root mean square error between predicted and experimentally observed values (Figure 
5.7 C).  For the preliminary dataset, only four outcomes were tested, 12 hr norm CTGF 





Figure 5.7. Refined PLSR analysis. A) Shows miRs that cluster with a certain function which 
can then be scored (B) for potential involvement, leading to regression analysis to determine 




5.4.7 Validation of statistical modeling 
To test the principle component analysis that 3 hr exosomes would have a 
diminished influence on cellular responses, we treated cardiac endothelial cells with 3 hr 
normoxic and hypoxic exosomes tested for tube formation (Figure 5.8). We found that, 
whereas tube formation was significantly increased by hypoxic 12 hr exosomes and not 
12 hr normoxic exosomes, the vasculogenic effects were removed in treatment with 






Figure 5.8. Validation of statistical modeling by tube formation. Whereas exosomes 
generated by hypoxic CPCs in 12 hr improved tube formation, treatment with exosomes 





Myocardial infarction can trigger death in billions of cardiac myocytes, but 
myocytes are largely non-proliferative and thus the local environment compensates by 
replacing the cells with non-contractile scar tissue.120 While this non-contractile tissue 
provides structural integrity, cardiac function suffers. No definitive treatments exist for MI, 
and a third of patients will progress toward heart failure.120 Cell-based therapies in the 
last decade have demonstrated the benefit of injected stem cells on LV function post-
MI.232-234 However, several major hurdles exist including cell retention, toxic engraftment 
environment, immunogenicity of transplanted cells, and temporal limitations in expanding 
autologous cells. Cardiac progenitor cells reside in the heart that may exert a beneficial 
influence, but their population is too small to substantially protect or repair the heart. 
Although injected stem and progenitor cells alike may differentiate into functional tissue, 
many researchers believe that the benefits are due to production of growth factors, 
cytokines, and other paracrine signals.138, 235-237 We postulated that substantially 
amplifying this signal would leverage endogenous reparative mechanisms, while side-
stepping hurdles involved with cell-based therapies. 
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Because CPCs are specialized to function in the heart, CPC-generated 
exosomes may be well-suited to treat cardiac pathologies. Very few studies have 
investigated the therapeutic potential of CPC exosomes. In one, the exosomes 
enhanced endothelial migration, indicating angiogenic effects.140 In another, CPC 
exosomes reduced myoblast apoptosis in vitro and decreased myocyte cell death in an 
animal MI model.141 However, exosomes were generated in normoxic conditions in both 
of these studies, not hypoxic conditions that may better reflect post-infarct tissue. 
Hypoxic preconditioning enhanced the benefit of CPC therapy for in an animal MI 
model,238 and as such, we hypothesized that CPC exosomes generated in hypoxic 
conditions would exert greater beneficial effects on cardiac cells (CECs and fibroblasts) 
than normoxic exosomes. Our findings indicate that hypoxic exosomes indeed benefitted 
the cells more so than normoxic exosomes, providing foundation for their development 
as a post-MI therapeutic. Additionally, statistical analysis of the miR exosome 
components may aid in the development of future bio-inspired therapeutics. 
In comparing normoxic and hypoxic exosomes, it was important to evaluate 
vesicle size, total miR or protein levels, or cell internalization rate as contributing factors 
in different downstream effects we might observe. All these being similar between the 
two groups, we ruled out differences in loaded amounts or uptake as causes of 
physiological response. While we did not evaluate mechanism of uptake, it could be 
different between the two groups as surface markers may change during hypoxia. We 
found punctate fluorescence in the cells which is interesting as there is debate whether 
exosomes deposit their contents by cell membrane fusion or active internalization.120 
Observation of ~1 um spots lent support to the latter and may agree with what other 
groups have been found, that exosomes are internalized via endocytic pathways and 
transported to the perinuclear region by the cytoskeleton.120, 135  
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We found that although normoxic exosomes had no effect on tube formation, 
there was a positive effect of hypoxic exosomes a low treatment levels, but that it 
plateaued after 0.1 mg/mL. These effects could be due to the increased intra-exosomal 
levels of pro-angiogenic miR-17239-241 and -210242-244. In fact, miR-210 has been explored 
as a potential therapeutic for the post-MI heart.244 Disruption of exosomes by means of 
sonication abrogated the effect of hypoxic exosomes on tube formation, indicating the 
need for intact exosomes and not just surface binding of membranes. Exosomes from 
other cell types and tissues have also been found to induce angiogenesis, though 
sometimes resulting in pathological states, such as in tumor growth.130, 138, 245, 246 
Additionally, relating to CPC exosomes, one study found that treatment with exosomes 
enhanced endothelial cell migration in a scratch wound assay.140 While not measured in 
the study, our data, along with these supporting data provide support for the angiogenic 
potential of CPC hypoxic exosomes. 
Fibroblasts respond to the remodeling environment during post-period by forming 
non-contractile scar tissue,247 and this paired with the extensive cardiomyocyte death 
and non-proliferation,120 leads to long-term dysfunction. Further, stimulation of fibroblasts 
with cytokines such as TGF-b in the damaged myocardium increases production of 
CTGF, and other factors.248 We found that our exosomes from hypoxic CPCs 
significantly decreased CTGF mRNA levels 42% from stimulated levels, while there was 
no effect of exosomes from normoxic CPCs. Aberrant CTGF expression is associated 
with cardiovascular disease and involved in fibrotic pathology, exacerbating extracellular 
matrix production.249 Studies have shown that deletion of CTGF reduces fibrosis.250 This 
decrease could potentially translate to reduced scar formation in vivo, which if combined 
with improved angiogenesis could lead to replacement of the lost tissue or enhanced 
survival of the host tissue.  The benefit of hypoxia-derived CPC exosomes could be due 
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to the increased levels of miR-17,251-253, -199a,254 -210,244 and -292,254 all of which have 
been demonstrated or predicted to regulate fibrosis. 
Cells have been shown to alter the secretion of bioactive molecules in varying 
conditions, including hypoxia.214 We examined extracellular miR release following 3 or 
12 hours by microarray.  Of those upregulated at least 2-fold by hypoxia at the 12 hour 
time point, we found that of the 11 miRs upregulated, seven were encapsulated by 
exosomes as confirmed by qRT-PCR. When we conducted a literature search on the 
upregulated miRs, we found most to regulate cardiac functions. We found that none of 
our eleven upregulated miRs have been previously discovered to regulate cardiac 
functions, though the human analog of miR-15b is upregulated in the circulation of 
patients with critical limb ischemia.255 These novel findings are therefore extremely 
useful to the scientific community, as a major development needed in the nascent 
cardiac exosome field is the characterization of exosomal contents. This will lead to 
better biomarkers for pathology and more effective therapeutics.  
Our array studies generated lots of data that may be difficult to attribute to a 
specific function.  Indeed, we measured over 750 mature miRs and found changes at the 
3 and 12 hour time point. To understand these data and potentially identify miR clusters 
that may regulate function, we employed principle component and partial least squares 
regression analyses and compared the effects of treatment conditions for exosome 
generation (cues) on specific miR levels (signals) and eventual physiological responses 
(tube formation, CTGF mRNA levels). This method served as a statistical instrument to 
generate a theoretical hypothesis based on empirical data. Whereas the exosomes 
initially explored for function were produced following 12 hours of normoxia or hypoxia, 
to generate and validate our model we also produced and examined the secreted 
miRnome of exosomes generated during 3 hours of hypoxia and normoxia. 
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We first examined the principle component analysis on the normalized data from 
the microarray to identify miR clusters that co-vary based on treatment condition. We 
were surprised to find that the majority of miRs clearly grouped into four major clusters.  
The black cluster is pro-hypoxic and blue is the opposite.  Red and green clusters do not 
respond to hypoxia (zero projection onto PC2, the hypoxia axis), but are the effects due 
to another currently unknown mechanism.  More interestingly, three of the 11 miRs 
secreted by CPCs and cluster with three of the groups miR-292 with the blue group, 
miR-20a with the green group, and mir-17 with the red group, but the others contribute to 
both oxygen treatment and time component induced cellular responses.  This is denoted 
by the magnitude of their distance from axes of PC2 and PC3. 
Our PLSR analysis first evaluated the total miR array results to establish a 
relationship between signals (individual miR levels) responding to the cues of exosome-
generating conditions and the downstream responses. Then the VIP (Variable 
Importance of Projection) were calculated to determine which signals have greatest 
projection/contribution towards a phenotypic outcome. We were surprised to observe 
such clear separation of 12 hr normoxic and hypoxic exosomes in the cues plot, and the 
clear separation of the tube formation and fibrosis in the response plot as well. More, 
CTGF mRNA levels co-vary with 12 hr normoxic exosome cues and tube formation co-
varies with 12 hr hypoxic exosome cues.  Of these top 100 miRs, it can be seen which 
miRs co-vary with CTGF mRNA and which co-vary with tube formation, that identify 
which miRs may be targeted for further investigation into these outcomes. 
To validate our computational model, we performed tube formation experiments 
with exosomes from CPCs exposed to hypoxia or normoxia for 3 hours. Whereas the 
separation of the 12 hour normoxic and hypoxic exosomes in the cues plot was profound, 
3 hour exosomes were hardly separated, predicting little difference in their effect on tube 
formation. When we performed our tube formation experiments with the 3 hour 
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exosomes, we saw no difference in their effects, validating the PLSR model. 
Interestingly, the model predicted that had any significant difference been observed, 3 
hour normoxic exosomes might have enhanced tube formation, albeit very minor. This is 
in contrast to the 12 hour exosomes, indicating that CPCs alter the exosome miR load 
not only as a function of oxygen levels, but also how long the CPCs are subjected to the 
conditions. 
A new PLSR model was created trained on the 11 upregulated miRs identified by 
microRNA array. This is the benefit of PLSR, in that it allows the reduction of large 
datasets to smaller, more informative datasets, reducing experimental burden while 
maintaining integrity and predictability of a dataset.  Figure 5.7 reflects that the 11 miRs 
actually maintain 98% predictability for the outcomes of tube formation and CTGF 
expression, while the full set of 383 miRs has closer to 100% predictability. Of note is the 
high scoring of miR-292, predicting its role as highly influential on tube formation and 
fibrosis. Studies are underway to determine the effects of miR-292 on tube formation 
and CTGF expression. 
In this report we show that CPCs release a beneficial signal in response to 
hypoxia, but that the population in vivo is likely too small to exert a substantial effect. We 
confirmed that CPCs secrete exosomes under both normoxic and hypoxic conditions, 
and that miR content is dynamically regulated based on time as well. Exosomes 
generated under hypoxic conditions for 12 hours enhanced endothelial tube formation 
and attenuated CTGF mRNA levels in stimulated fibroblasts, supporting the potential of 
hypoxia-derived exosomes as a potential therapeutic agent. Based on our results, we 
developed an empirically derived computational model to determine how exosome-
generating conditions, miRs, and physiological responses co-vary. Our findings support 
the development of hypoxic CPC-derived exosomes as naturally derived therapeutics 
and lay the groundwork for statistical models that—by characterizing the relationship 
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among exosome generating conditions, miR regulation, and physiological responses—








6.1 GlcNAc and PCADK particles 
Since their development in our collaborating lab in 2006, the pH-sensitive 
polyketal polymers—of which PCADK is a member—have been explored in a range of 
therapeutic settings, with the biocompatibility of their degradation products being a key 
benefit. The polymer has been used to form non-water soluble micro- and nanoparticles 
and shown to encapsulate small molecules and proteins. However, our study was the 
first to decorate the surface with ligands to trigger uptake by non-phagocytic cells. 
Cardiomyocytes internalized the particles for the intracellular delivery of an anti-apoptotic 
molecule, and we found decreased myocyte death and improved cardiac function in a rat 
IR model. 
Our in vivo findings were crucial, as our delivery system addressed the acute 
phase wherein apoptotic pathways are triggered immediately during and after MI. 
However, long-term effects of our novel system would be important to explore. We may 
find that decreased myocyte death leads to a reduced pressure overload and less 
fibrotic scarring. Additionally, an influx of the phagocytic macrophages presents another 
opportunity; that a combination of delivery of these PK-GlcNAc-SB particles to both 
moycytes and macrophages could create a synergestic effect to attenuate cardiac 
dysregulation. Another application of PK-GlcNAc particles worth exploring is the delivery 
of cell-impermeant proteins to CMs, as this would open delivery of a large class of 
protective proteins to ischemic myocytes. 
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Recent findings out of a research lab at University of Louisville has demonstrated 
the cardioprotective effects of GlcNAc on CMs256 and CPCs257, potentially enhancing the 
therapeutic effects of GlcNAc-presenting delivery systems. In fact, one of our 
collaborators has been evaluating the regenerative potential of empty PK-GlcNAc 
particles. Since the completion of our work as it currently stands, nine research articles 
have been published on polyketal particles,258-265 indicating the increasing interest in the 
scientific community on these particles as delivery vehicles. 
6.2 Regio-selectively decorated dendrimers 
We found that our RGD-bowtie effectively transfected cells with miR by 
enhancing angiogenesis, increasing cell proliferation. Importantly, our dendrimeric 
vehicle did not exhibit cytotoxicity, an effect that many dendrimers elicit. Depending on 
application, cellular toxicity may be a benefit or undesirable, but as we aim to create a 
pro-regenerative environment, toxicity would be deleterious. 
Our finding that different materials elicit different responses is not entirely 
surprising; the processes between internalization of miR-loaded vehicles and cell 
proliferation or tube formation is complex and may be perturbed by various material 
features. In addition to tuning vehicle design for desired extracellular interactions and 
uptake, investigation of the intracellular interactions and subsequent effects are essential 
in the development of effective transfection vehicles. The bowtie template affords a wide 
range of possibilities for tuning parameters and properties, such as ligand and charge 
densities, dendron size, and incorporation of other specialized bioactive groups (e.g., 
aptamers, saccharides, and antibodies).14 In turn, these design alterations may influence 
binding avidity and specificity, multivalent interactions, cargo capacity, cytotoxicity, 
endosomal escape, immunogenicity, and stability. Keeping these research 
considerations in mind, we plan on further developing our bowtie structure in the near 
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term by increasing RGD peptide density on RGD-bowtie and N/P ratio to further 
enhance transfection. In the long term, we will characterize uptake kinetics in relation to 
ligand density and dendrimer size, examine the electrostatic binding and loading of miR 
to the cationic region of the bowtie, and investigate bowtie modification with other 
ligands to enhance uptake and cell specificity.  
In in vivo application, a single dose of the dendrimer bowtie may transfect the 
cells in the acute phase. However, should the infarct become reperfused, the small size 
and solubility of these dendrimers may allow their clearance. A strategy for prolonged 
treatment may be loading the bowties into a hydrogel for sustained delivery and regional 
retention. 
6.3 Exosomes and the heart 
Previous findings have shown the benefit of the secretome of CPCs in treating 
the MI heart, but ours was the first to study how exosomes generated in hypoxic 
conditions—that mimic ischemia—might affect the physiology of cardiac cells. We found 
them to improve the tube formation of cardiac endothelial cells and reduce fibrotic mRNA 
in cardiac fibroblasts. This may have the effects of enhancing blood flow to the infarct 
and reducing non-contractile scar formation. Additionally, we found several miRs to be 
upregulated in hypoxic exosomes. While we correlated upregulated exosomal miRs with 
beneficial cellular effects, we have yet to show causation. To do so, our plans in the near 
future include inhibiting the ribonucleic acid-induced silencing complex (RISC) and 
observing reducing impact of hypoxic exosomes. Additionally, as our study postulated a 
role of miR-292 (that has heretofore been unexplored), we will repeat our cell 
experiments with co-transfection of anti-mir-292. 
Our statistical modeling has provided insight into future bio-inspired therapeutics. 
With the knowledge that CPCs produce exosomes that may be internalized by cardiac 
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cells, engineering of these exosomes with miR cocktails may allow for tuned therapies. 
PC analysis identified miRs that co-varied and predicted their function. Creating a CPC 
line that overexpressed a desired miR cassette, and generating exosomes from the line 
may be one route for future therapies. 
The field of cardiac exosomes is in its infancy, and several broad questions 
remain to be answered, some of which we have attempted to address in part. Namely, 
how does the myocardium initiate the local repair process? Are exosomes shuttles for 
unwanted material, or cell-cell communicators? Do secreted exosomes from the heart 
have any physiological function? Do secreted cardiac exosomes function in autocrine, 
paracrine, or endocrine signaling, or a combination? If one of their roles is endocrine, 
then could they be recruiting cells, such as bone marrow, to the infarct and conditioning 
them en route? Research efforts to answer these questions will yield a greater 
understanding of the heart and provide for development of naturally derived therapies 
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